

### BRITISH LIBRARY OF POLITICAL AND ECONOMIC SCIENCE



LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE 10,PORTUGAL STREET, LONDON WC2A 2HD Tel. 01-405 7686

#### BRITISH LIBRARY OF POLITICAL AND ECONOMIC SCIENCE

The London School of Economics & Political Science 10 Portugal Street, London WC2A 2HD Telephone: 01 - 405 7686

and the second		
		-

GENERAL REGISTER OFFICE

THE REGISTRAR GENERAL'S

() 5142 (MATO

42

## STATISTICAL REVIEW OF

## ENGLAND AND WALES FOR THE YEAR 1961

SUPPLEMENT ON CANCER



1878/4

#### LONDON HER MAJESTY'S STATIONERY OFFICE

Price 7s. 6d. net

#### GENERAL REGISTER OFFICE

### STUDIES ON MEDICAL AND POPULATION SUBJECTS

#### No. 19

## Regional and Social Factors in Infant Mortality

эу

C. C. Spicer, M.R.C.S., L.R.C.P., Dip. Bact., Dip.S.S. and L. Lipworth, M.B., Ch.B., B.Sc.

This study gives the results of a special investigation carried out by the General Register Office into the pattern of over 14,000 stillbirths and over 17,000 infant deaths registered in England and Wales in the twelve months April 1964 to March 1965.

The factors studied in the investigation were social class of father, parity and age of mother, and the geographical region to which the birth was assigned. The detailed tables, which it is hoped will be of value to research workers who may wish to make a further study of the subject, are prefaced by a short commentary which draws attention to the more significant findings and describes the methods adopted in the enquiry—in particular, those adopted for the statistical analysis of the data.

#### Price 7s. 6d. net (By post 7s. 11d.)

#### Published by

#### HER MAJESTY'S STATIONERY OFFICE

and obtainable from the Government Bookshops in London (post orders to P.O. Box 569, S.E.I), Edinburgh, Cardiff, Belfast, Manchester, Birmingham and Bristol, or through any bookseller GENERAL REGISTER OFFICE

THE REGISTRAR GENERAL'S STATISTICAL REVIEW OF

## ENGLAND AND WALES

FOR THE YEAR 1961

### SUPPLEMENT ON CANCER

LONDON HER MAJESTY'S STATIONERY OFFICE 1967

#### TABLE OF CONTENTS

#### The National Cancer Registration Scheme

Progress in Cancer Registration since 1953	1
Scope of the Present Report	
Survival analysis Incidence of cancer in England and Wales, 1961 Definitions	3
Survival in the second five years after treatment	5
Effect of delay in cancer of the breast	9
Survival in cancer of the cervix	
Carcinoma of the uterine corpus	19
Cancer of the prostate	23
Malignant disease of the testis	27
Trends in the prognosis of chronic leukaemia	31

#### Diagrams

	Diagram 1.	Breast cancer. 5-year crude survival percentages	0
	Diagram 2.	Localised cancer of prostate. Age-corrected survival percentages. Under 70 years of age2	5
	Diagram 3.	Chronic lymphatic leukaemia. Comparison of age-corrected survival percentages	3
Te	xt Tables		
	Table 1.	Five- and ten-year survival percentages for confirmed cases of different sites by sex and stage of the disease - 1948-49 registrations	6

#### ACKNOWLEDGEMENT

The survival data contained in this volume has been derived mainly from material produced for the International Symposium on the End Results of Cancer Therapy held in Sandefjord, Norway, in September 1963. The National Cancer Institute of the United States Public Health Service kindly undertook the processing of cancer registration material for a number of the countries participating in the Symposium, and made available to the General Register Office tabulations relating to England and Wales. The Registrar General recognises the valuable contribution towards the production of this volume thus provided by the National Cancer Institute and is most grateful to them for their generous assistance.

General Register Office, Somerset House, London, W.C.2.

October 1966

Page

Page

		0
Table 2.	Cancer of the breast. Numbers of patients registered in 1954-55 and 5-year survival percentages by symptomatic history	12
Table 3.	Cancer of the breast. Percentages of patients registered in 1950-53 for durations of symptomatic history by each clinical stage. Estimated 5-year survival percentages	12
Table 4.	Cancer of the cervix (confirmed and not confirmed) 1952-53 registrations. Age-corrected 5-year survival rates by age, stage and form of treatment.	16
Table 5.	Cancer of the cervix. Mortality by social class, 1949-53	17
Table 6.	Cancer of the cervix, 1949 registrations. 5-year survival rates (crude and age-corrected) and percentage with localised disease by social class	18
Table 7.	Numbers and percentages of cases of carcinoma of the uterine body by stage and form of treatment	19
Table 8.	Five-year age-corrected survival percentages of carcinoma of the uterine body by age and treatment category (confirmed and not confirmed)	21
Table 9.	Five-year age-corrected survival percentages of carcinoma of the uterine body by clinical stage and treatment category	21
Table 10.	Five-year age-corrected survival percentages of cancer of the prostate by age, stage and form of treatment	23
Table 11.	Five-year age-corrected survival percentages among non-localised cases of cancer of the prostate for two periods by age and form of treatment	24
Table 12.	Five-year age-corrected survival percentages of confirmed cases of malignant disease of the testis by stage and form of treatment	29
Table 13.	Numbers of patients with chronic lymphatic and myeloid leukaemia and proportions by method of treatment.	31
Table 14.	Chronic lymphatic and chronic myeloid leukaemia, two- and five-year age-corrected survival percentages	32

#### Appendix Tables

Appendix Table A.	Registrations of newly diagnosed cases of cancer among males by site and age. England and Wales, 1961
Appendix Table B.	Registrations of newly diagnosed cases of cancer among females by site and age. England and Wales, 1961
Appendix Table C.	Registrations of newly diagnosed cases of cancer among males by site and age. Urban areas of England and Wales, 196140
Appendix Table D.	Registrations of newly diagnosed cases of cancer among females by site and age. Urban areas of England and Wales, 1961
Appendix Table E.	Registrations of newly diagnosed cases of cancer among males by site and age. Rural areas of England and Wales 1961
Appendix Table F.	Registrations of newly diagnosed cases of cancer among females by site and age. Rural areas of England and Wales, 1961
Appendix Table G.	Cases of cancer of selected sites by age,
Rospical Report	sex and stage of growth. Percentages of cases staged. England and Wales, 1961
Appendix Table H.	Cases of cancer of selected sites by sex, showing the total number staged and the number of early growths without clinical involvement of lymphatic glands. England and Wales, 1961
Appendix Table J.	Cases of cancer of the breast (females only) staged in accordance with the system recommended by the International Union against Cancer, by age. England and Wales, 1961
Appendix Table K.	Cases of cancer of the cervix by age and International stage. England and Wales 1961

iv

v

Page

Appendix Tables

## Appendix Taple A. Bajferrationa of Tably Misinger

Appendix Table"S. ""effectivefonds of "seein discontant sine of cancer cantin" sealer by the second of the second

an open and 22 for an inter a case of the same restrict.

Design there a of encer shore females by site and

Appendix Tably Last appendix of maly discussed the set of the set

upendix fable and "Registerificated healy mianized onces of ender anong femles by site and ago, several trees of Sagland and agen, noo

mendia fable G. Conserver SuindPat Saletted Afree by Ant. See and stated of around. Perceptions of any mendia fabre stated. "Encland and Malane and

Table 1. Cases of Sanash of Addied and a second the showing the total mutter staged and the is and a second of sange gradeau without the to see

### THE NATIONAL CANCER REGISTRATION SCHEME

## Progress in Cancer Registration since 1953

The history of the National Cancer Registration Scheme was described in the Supplement on Cancer to the Registrar General's Statistical Review of England and Wales for 1953. Since that year the coverage has continued to increase, and by January 1962, all the hospital regions in England and the Welsh Hospital Board had established registries. The practice, initiated by the General Register Office in 1957, of sending copies of death entries with mention of cancer to the relevant regional registries has likewise spread to all regions which require them. It would be incorrect to assume, however, that this has played more than a minor part in the improvement in coverage; this is largely dependent on the support of hospital staff, medical and recording, as well as the enthusiasm of the regional registries.

The figures in the following table compare the registration rates for 1953 and 1961. It should be pointed out that comparisons between the two years for each region are affected to some extent by a change in the basis of assignment of cases. For the earlier year, the rates are based on the registrations within each region whilst those for 1961 show the incidence among the populations resident in each hospital region.

Table showing the registration rate per 1,000 population by hospital regions for 1953 and 1961

A PART & CAR A PART AND PART		
Hospital Region	1953 Registrations	1961 Registrations by region of domicile
Newcastle	1.7	2.6
Leeds	1.3	2.7
Sheffield	1.2	2.5
East Anglia	1.6	2.8
N.W. Metropolitan N.E. " S.E. " S.W. " Wessex	1.5 1.3 1.1 ] 1.4	2.7
Oxford	2.4	2.7
South Western	2.3	3.0
Wales	1.0	2.3
Birmingham	1.6	2.6
Manchester*	1.1	orteinal grant les artes del
Liverpool	2.0	2.8
All Regions	1.5	2.4

\*Manchester region was not participating in the Scheme in 1961.

There is reason to believe that the coverage is very much better for age-groups below 65 years for all malignant diseases (except of the skin, for which coverage is a special problem as explained below). Several regional registries have found from a comparison of copies of death entries mentioning cancer with registrations that it is the elderly patient who is frequently not admitted to hospital. This was shown, too, in figures collected by the South Western Regional Cancer Bureau and published in their Annual Report for 1954. Skin cancer is often dealt with in out-patients' departments, and though strenuous efforts are made to obtain notifications of all patients with malignant disease of the skin, it is generally more difficult to do so when patients are not admitted to hospital.

There is varying coverage in different age-groups but an important example between the under and over 65 years groups is the case of carcinoma of the cervix. There were 1.8 times as many registrations in 1961 as deaths due to this cause under the age of 65 compared with the corresponding ratio of 1.5 to 1 for all ages. (These ratios would be somewhat higher for 1962 and later years following the inclusion in the Scheme of the Manchester hospital region.)

weight the sources read of an of a the source in 1222.

and ignor plands (trraspective of the stage of the primary

The states thed for the munuts of the cervix tiert in Appendix Table 6 are those recommended by the Jorid Healt

#### SCOPE OF THE PRESENT REPORT

#### Survival analysis

This report contains survival analyses for a number of specific sites based on 1952-53 registrations and using, in certain instances, 1948-49 cases for purposes of comparison. The sites selected are cancer of the cervix (with survival shown by social class for 1949 patients), uterine body, prostate, testis and leukaemia. There is also an examination of survival in the second five years after treatment for several sites, based on 1948-49 registrations, and discussion of the effect of delay on prognosis in breast cancer, based on 1954-55 registrations.

#### Incidence of cancer in England and Wales, 1961

The 1961 registrations of newly diagnosed cases of cancer in England and Wales form the basis of the incidence figures by site, age, sex and area (urban or rural) shown in the Appendix Tables, as well as of the staging of the growths.

If the population at risk is limited to the 41.7 million people of England and Wales in 1961 domiciled outside the Manchester Hospital Region, (which did not join the Scheme until 1962) the figures presented probably cover a high percentage of the diagnosed cases, particularly those under the age of 65 years. In the *Report of the Chief Medical Officer of Health*, 1957, Part II, it was suggested that the yearly incidence of all forms of cancer, including those cases which never attended hospital, was probably about 3 per thousand of the population, although this may be an underestimate and was itself a correction of a previous figure of 2.5 per thousand. Latterly the figure of 3.1 per thousand has been used to represent complete coverage. (This figure has recently been exceeded in some areas of the South Western Region.) This would mean that the 111,613 registrations in 1961 correspond to a coverage of 86 per cent of the 41.7 millions of people defined above.

#### Definitions

The following definitions are provided to assist in the understanding and interpretation of this report.

Stage: For much of the commentary, two stages only are identified, viz: "localised" and "not localised". Broadly, a "localised" (or "early") growth is one "limited to the organ of origin". For a growth within the oral cavity, "localised" (or "early") is defined as one which has an estimated diameter of less than 4 cms.

In Appendix Tables G and H, the stage groupings used are defined as follows:-

- EP<sub>0</sub>, EP<sub>s</sub>. An early growth with (s) or without (o) clinical involvement of lymphatic glands.
- LP<sub>0</sub>, LP<sub>s</sub>. A late stage growth (i.e. the original growth had extended to adjoining organs, or firm fixation had occurred; or in the case of the oral cavity the growth exceeded 4 cms. in diameter) - with (s) or without (o)

Metastases present: Metastases were detected in organs other than lymph glands (irrespective of the stage of the primary growth).

The stages used for the tumours of the cervix uteri in Appendix Table K are those recommended by the World Health Organisation.

The T.N.M. system of staging breast cancer used in Appendix Table J is that recommended by the International Union against Cancer.

Survival rates are calculated from the proportions surviving each year. Age-corrected rates, or the relative survival rates, refer to results where correction has been made for the risk due to competing causes of death, such as heart disease. the incidence of which varies with the age and sex of the patient. The reason for this adjustment is that all deaths in patients treated for cancer are considered failures, as it is impossible in many cases to find out how much the malignant disease contributed to the fatal outcome. As an example of the method, if 60 per cent of treated cases survive five years and the expected survival for five years of the population at large with the same age distribution as the patients is 95 per cent as shown by national life tables, then the corrected survival is 60% \_ 63 per cent. .95

#### SURVIVAL IN THE SECOND FIVE YEARS AFTER TREATMENT

It is customary to calculate survival rates in cancer as the percentage surviving five years after treatment, possibly because it was previously considered that, in general, patients surviving five years were cured. The period of survival usually considered as that indicating eradication of the growth, however, is measured by the time taken for the annual death rate of a group of sufferers to fall to the level of that of the general population with the same age distribution. This period is frequently more than ten years and indeed the annual survival may never attain the level of the general population, as in the cases of patients with mammary cancer, in whom there is a tendency to malignant disease of the remaining breast. Nevertheless the prognosis tends to improve with each year survived.

Survival figures for the first and second quinquennia for several sites. are presented below. All the results are confined to cases confirmed by histology, in view of the long period over which the survival is measured. The percentages of patients shown to have survived the second five years are based on the number who were alive at the commencement of the sixth year after treatment. The results for the second quinquennium confirm the much better prognosis of patients in this period. Prostatic cancer shows the poorest 5-10- year survival (age corrected rate 67.5 per cent for all stages) in spite of fair results in the first five years compared with other sites. For this reason it has been advocated that in comparisons of treatments of prostatic cancer, 10-year survival figures ought to be considered as well.\*

The clinical stage of any malignant growth at the time of treatment had much less effect on the prognosis in patients who had already survived five years than it had in the first five years, although patients with localised growths in general still showed better results. A notable exception was cancer of the large intestine in both sexes, where the 5-10 year survival was better in cases with disease that had not been considered to be localised.

\*Hudson, P. "Hormonal control of prostatic cancer". Cancer, Vol. 6. 1959, Butterworth and Co. Ltd., London.

		5-year percentage survival			5 <b></b> 10 <b></b> y	5-10-year percentage survival			
Site	Clinical stage	No. of cases	Crude survival (actual percentage surviving)	Age- corrected survival	No. of cases	Crude survival (actual percentage surviving)	Age <del>~</del> corrected survival		
Tongue	All stages	523	24.9	33.4	129	57.7	79.9		
(Males)	Localised	227	41.5	56.1	93	59.6	82.4		
Million and Marine	Not localised	296	12.2	16.3	36	52.7	73.4		
(Females)	All stages	208	37.1	43.9	76	69.7	88.3		
	Localised	120	49.8	59.1	59	71.1	89.8		
	Not localised	88	19.6	23.2	17	64.7	82.8		
Oesophagus	All stages	501	2.4	3.1	12	91.6	100.0		
(Males)	Localised	83	4.8	6.2	4	100.0	100.0		
(110100)	Not localised	418	1.9	2.5	8	87.5	100.0		
(Females)	All stages	247	3.4	4.0	8	75.0	87.4		
(remares)	Localised	58	10.3	11.9	6	66.6	76.1		
	Not localised	189	1.2	1.4	2	100.0	100.0		
Stomach	All stages	1,208	9.2	11.0	109	66.8	80.6		
(Males)	Localised	302	21.9	25.4	64	70.1	84.4		
(HALOD)	Not localised	906	5.0	6.1	45	62.2	75.2		
(Females)	All stages	710	9.7	11.0	68	68.3	77.6		
(10110120-)	Localised	163	26.7	29.7	43	69.7	77.3		
	Not localised	547	4.6	5.3	25	65.4	77.7		
Large intestine	All stages	886	27.5	34.6	242	65.1	85.5		
(Males)	Localised	379	45.0	56.7	170	63.3	84.4		
	Not localised	507	14.3	18.1	72	69.4	87.9		
(Females)	All stages	1,098	31.5	35.8	341	75.6	88.8		
(,	Localised	494	A CONTRACTOR OF A CONTRACT OF	55.2	238	74.3	87.5		
	Not localised	604	17.3	19.8	103	78.6	91.8		
Rectum	All stages	1,507	30.6	38.3	459	64.2	85.2		
(Males)	Localised	745		54.4	325	66.1	87.1		
(	Not localised	762	17.9	22.5	134	59.7	80.7		
(Females)	All stages	955	34.5	39.2	324	71.9	85.3		
(3	Localised	480	Standard and a state of the second of	59.7	249	74.5	87.8		
	Not localised	475		18.2	75	63.3	76.6		
Lung and bronchus	All stages	2.741	3.7	4.2	102	67.6	76.9		
(Males)	Localised	425		16.5	63	A TALAN STRUCTURE IN PROPERTY.	80.3		
(	Not localised	and the second second	DE LA CARA DA ANNA DE LA CARA DE LA CAR	1.9	39	64.1	71.7		

# Table I. Five- and ten-year survival percentages for confirmed cases of cancer of different sites by sex and stage of the disease - 1948-49 registrations

Table I continued

		5-year percentage survival			5-10-year percentage survival		
Site	Clinical stage	No. of cases	Crude survival (actual percentage surviving)	Age- corrected survival	No. of cases	Crude survival (actual percentage surviving)	Age- corrected survival
Lung and bronchus	All stages	385	2.3	2.5	9	100.0	100.0
(Females)	Localised	38	10.5	11.0	4	100.0	100.0
	Not localised	347	1.4	1.6	5	100.0	100.0
Breast (Females)	All stages	6,909	48.4	53.3	3,326	68.0	77.9
	Localised	2,667	65.1	71.2	1,723	73.5	83.7
	Not localised		37.4	41.2	1,532	62.3	71.3
Uterine corpus	All stages	1,017	51.5	57.8	520	78.1	89.3
o ber me bor pub	Localised	551	62.2	69.8	341	79.3	90.6
	Not localised	372	30.6	34.7	112	71.4	82.2
Uterine cervix	All stages	4.448	37.4	40.6	1,651	76.3	85.6
O DET THE OCT VIX	Localised	2,189	50.7	54.7	1,105	78.3	87.5
	Not localised	INCOMPANY CONCLUSION	23.0	25.2	497	70.9	80.8
Ovary	All stages	1,085	21.8	23.5	232	78.7	86.0
U Tur J	Localised	283	50.2	53.7	139	81.0	88.5
	Not localised	802	11.7	12.6	93	75.2	82.3
Testis Seminoma	All stages	168	53.5	56.5	89	88.4	95.1
	Localised	107	67.2	70.7	71	92.7	98.3
	Not localised	61	29.5	31.3	18	72.2	82.4
Teratoma	All stages	78	47.4	49.6	36	91.5	96.0
	Localised	47	_65.9	69.7	30	93.3	97.2
	Not localised	31	19.3	19.9	6	83.3	90.2
Prostate	All stages	686	25.8	38.1	176	43.6	67.5
	Localised	262	34.3	53.9	90	38.2	61.6
	Not localised	316	12.7	18.6	40	38.5	59.0
Melanoma	All stages	142	37.9	46.7	52	72.9	91.3
(Males)	Localised	86	50.6	63.2	42	Construction and a second state of the	85.8
	Not localised	56	18.3	22.1	10	90.0	100.0
(Females)	All stages	178	51.5	58.0	90	The second s	83.9
	Localised	117	A REAL AND A REAL PROPERTY AND A	70.4	74	and the second second second second	82.7
	Not localised	61	28.9	33.1	16	81.2	89.4
				11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		and Lords	TRACE

6

in it of the set of the set of the set of the state of the set of the

#### EFFECT OF DELAY IN CANCER OF THE BREAST

Although early treatment is always advocated in malignant disease, there is by no means a universal agreement that length of delay in reporting after onset of symptoms greatly affects the prognosis. Among the factors affecting the time of onset of symptoms, the degree of malignancy between cancers of the same organ (Bloom 1950)<sup>1</sup> must be mentioned since highly malignant growths tend to occur more frequently among patients who report with breast cancer soon after they become aware of symptoms and more slowly growing tumours among those who report late. (Sutherland 1960)<sup>2</sup>.

The experience of 21,018 cases of female breast cancer registered in 1954-55 in England and Wales was examined to find what relationship, if any, existed between duration of symptoms before reporting and prognosis as shown by the 5-year survival percentage.

One step in the investigation was to determine the relationship of the stage of advancement of the breast cancer to both the delay and the eventual survival. It has been shown from cases registered in 1945-47<sup>o</sup> that provided the growth was found to be localised on reporting, the prognosis was not affected by the delay. In the case of late primary growth the survival was better in patients who either reported within two months of symptomatic onset or postponed reporting for more than a year than in patients whose period of delay was intermediate. MacKay and Sellers<sup>4</sup> in a study of breast cancer registrations in the Ontario Cancer Clinics found that within each stage of spread, survival seldom varied with delay. The records of a further 27,063 patients with breast cancer registered in 1950-53 were therefore examined for the effect of delay in reporting on the clinical stage of spread. The findings from this investigation, viz. in general that early reporting is worthwhile, were compared with those obtained from the registrations of breast cancer in 1954-55, as mentioned above.

Over 99 per cent of the female cases of breast cancer registered in 1954-55 were followed up for five years. The duration of symptomatic history was not stated in 1,891 cases, leaving 91 per cent of the cases for analysis.

The crude 5-year survival rates shown in Table 2 were calculated for patients with similar periods of delay by the Life Table method<sup>5</sup>.

Patients registered in 1950-53 were likewise separated into groups with the same period of delay, and each of these again into the proportions with tumours in the following five clinical stages of spread (Table 3).

- (1) EP<sub>0</sub> localised primary growth, that is not infiltrating neighbouring structures apart from the skin in the region of the growth, and without lymph gland involvement.
- (2) EP<sub>s</sub> localised primary growth but with involvement of axillary lymph glands.
- (3) LP<sub>0</sub> late primary growths, no lymph gland involvement.
- (4) LP<sub>S</sub> late primary growths with axillary lymph gland involvement.

9

(5) Met.- clinical evidence of metastases.

For radically treated patients registered in 1945-47 the average 5-year survival percentage is known for each of these stages separately<sup>3</sup>. By applying these survival figures to the percentage of cases in the corresponding clinical stage at each duration an expected 5-year survival percentage was obtained for patients registered in 1950-53 as shown in Table 3. The survival at each duration calculated in this way from the clinical staging distribution is compared with the actual survival of patients registered in 1954-55 in Diagram 1.

Diagram I

## BREAST CANCER. 5-YEAR CRUDE SURVIVAL PERCENTAGES 1954-55 registrations - Actual survival Survival O 1950-53 registrations - Survival estimated from stage percentage of spread on reporting 60 50 00 0 0 40 0 0 0 0 0 30 24 12 18 Duration of symptomatic history (months)

It can be seen from Table 2 that, as delay before seeking treatment increased, the prognosis deteriorated from a 5-year survival of 54 per cent in those reporting in the first month to 38 per cent in those delaying over two years. Diagram 1 also shows that the change in prognosis was most noticeable in the early months, both in the actual survival of the patients registered in 1954-55 and in the expected survival of those registered in 1950-53. It appears from Diagram 1 that the actual survival and that derived from the clinical stage follow a similar course but the calculated survival of patients registered in 1950-53 is consistently less than that observed in patients registered in 1954-55. This is in keeping with the improved prognosis in later years in England and Wales since the survival figures used for the calculation were those of patients registered in 1945-47 when the overall 5-year crude survival was 33 per cent as against 44 per cent in 1954-55.

If the results shown in Diagram 1 are valid it appears that speed in initiating radical treatment is particularly important in patients who give a history of recent onset, though delay at any stage may be harmful. However, unusually rapid growth of the tumour, with early onset of pain or skin involvement, may force some patients to seek medical attention soon after the onset of symptoms and, therefore, the deterioration in the prognosis in groups of patients who report after increasing periods of delay may give a false picture of the rate of spread of the tumour in the average case. For example, if in a group of patients with the same duration of symptoms those reporting without further delay are those with more advanced tumours, then the prognosis of the whole group could have been greatly improved if the less advanced cases had reported earlier also, rather than later when they had reached a more serious stage of the disease.

A further weakness of methods used to analyse the effect of delay on the prognosis in malignant disease is that they are not directly applicable to the results in cases diagnosed at cancer detection centres where the tumour is frequently in the pre-symptomatic stage. For example, in rectal cancer, excellent results were obtained at the Cancer Detection Centre, Minnesota (Gilbertsen V. A., Wangensteen O. H. 1964)<sup>5</sup> whereas in registrations of rectal cancer in England and Wales in 1945-47 the prognosis improved with the length of symptomatic history<sup>5</sup>. On the other hand, the 5-year crude survival of 89 per cent in 44 cases of mammary cancer in patients regularly seen at this Cancer Detection Centre would appear to confirm the finding of the above analysis that the deterioration in prognosis is greater in the early history of the average growth.

MacKay and Sellars<sup>4</sup> suggested that the absence of the effect of delay on survival of patients in each stage of spread indicated that the stage of spread rather than the previous rate of growth determined the outcome. The adverse effect of delay on the prognosis as shown both from the clinical stage of growths of patients reporting after various periods of delay (Diagram 1) and their survival rates is in keeping with this.




Table 2. Cancer of the breast Numbers of patients registered in 1954-55 and 5-year survival percentages by duration of symptomatic history

Duration of symptomatic history (months)	Number of patients	5-year survival percentages		
0-	958	53.69		
1-	2,845	50.17		
2-	2,460	49.25		
3-	2,006	46.61		
4-	1,385	47.59		
5–	1,024	44.09		
6-	2,415	40.71		
9-	908	43.50		
12-	1,793	39.30		
18-	666	38.34		
24 and over	2,667	37.51		
Not stated	1,891	35.63		
All durations	21,018	43.83		

lable 3.	Cancer of the breast
	Percentages of patients registered in 1950-53 for durations of symptomatic history by each clinical stage Estimated 5-year survival percentages
	Estimated 5-year survival percentages

Duration of symptomatic	Stage			Metastatic	A11	Estimated 5-year	
history	EPo	EPs	LPo	LPs	Cases	cases	survival percentage
Months	%	%	%	%	%	Number (=100%)	12000 0000
0- 1- 2- 3- 4- 5- 6- 9- 12-18 18-20 21 and over Not known	46.0 44.7 41.0 38.7 35.6 33.5 28.6 25.9 24.4 19.7 20.3 31.4	23.7 24.7 22.5 20.9 19.4 19.8 17.9 18.5 14.5 15.4 10.4 12.1	5.9 5.6 6.3 7.6 8.7 8.3 9.2 9.3 10.5 10.7 13.9 12.0	17.7 20.8 24.4 27.1 29.7 29.5 33.1 34.4 38.5 42.8 39.2 30.0	$\begin{array}{c} 6.7\\ 4.2\\ 5.8\\ 5.7\\ 6.6\\ 8.9\\ 11.2\\ 11.9\\ 12.1\\ 11.4\\ 16.2\\ 14.5\end{array}$	1,139 3,502 3,181 2,591 1,708 1,295 3,217 1,327 2,726 598 4,085 1,694	44 44 42 41 40 38 36 35 35 34 32 31 36

The 5-year crude survival rates of cases of breast cancer registered in The b-year crude survival rates of cases of breast cancer registered in 1945-47 were 60 per cent for stage EP<sub>0</sub>, 43 per cent for stage EP<sub>5</sub>, 35 per cent for stage LP<sub>0</sub>, 22 per cent for stage LP<sub>5</sub>, and 5 per cent for metastatic cases. The estimated survivals shown were obtained by summing the products of these survivals with the proportion in the corresponding stage. For example, in those with delay of less than 1 month,  $(\frac{46.0}{100} \times 60) + (\frac{23.7}{100} \times 43) + (\frac{5.9}{100} \times 35) + (\frac{17.7}{100} \times 22) + (\frac{6.7}{100} \times 5) = 44.$ 

#### References

- 1. Bloom, H. J. C. (1950). Prognosis in Carcinoma of the breast, British Journal of Cancer. Vol. 4.
- 2. Sutherland, R. (1960). Cancer the significance of delay. Butterworth and Co. Ltd., London.
- 3. Supplement on Cancer to the Registrar General's Statistical Review of England and Wales for 1952. H.M.S.O.
- 4. MacKay, E. N., Sellers, A. H. (1965). Breast cancer at the Ontario cancer clinics 1938-1956: a statistical review. .Canad. Med. Assoc. J. Vol. 92. No. 13.
- 5. Int. Symp. End Results of Cancer Therapy, NCI Monograph No. 15, Bethesda, 1964.

## SURVIVAL IN CANCER OF THE CERVIX

5,580 cases (confirmed and unconfirmed) of cancer of the cervix were registered in 1952-53. In 50 per cent of these patients the disease was considered to be localised on clinical examination, i.e. showing no evidence of spread beyond the upper third of the vagina or the inner half of the parametrium. The remainder were classified as having non-localised growths, only two stages of spread being used in the analysis. Ninety per cent of all patients had had histological confirmation of their neoplasm.

#### Methods of treatment

Three quarters of the patients were treated by radiotherapy, this proportion applying equally to those with early growths and to those where the disease was no longer localised. A further 16 per cent of all patients with localised disease had surgery with radiation and 8 per cent surgery only. Of those with more advanced disease, on the other hand, 12 per cent were recorded as having had no known treatment.

#### End results

Thirty-eight per cent of all cases with cancer of the cervix survived five years, the age-corrected survival, which adjusts for the increased risk of death from other causes at older ages, being 42 per cent. For localised cases the age-corrected survival was 59 per cent compared with 24 per cent for the patients with more advanced disease. It can be seen from Table 4 that these results were significantly better than those of the patients registered in 1948-49, and that this was also true for all patients treated by surgery or surgery combined with radiation.

The poorer result recorded for all patients 65 years of age and over taken together (Table 4) when compared with younger age-groups can be accounted for by the smaller proportion of localised cases (43 per cent as compared with 50 per cent for all ages combined) in this age-group, for no clear trend with age can be shown in each of the separate stages.

Survival after different forms of treatment was probably affected by the selection of cases, the best results following surgery for which the five-year age-corrected survival was 62.0 per cent as compared with 55.6 per cent for surgery combined with radiation and 41.2 per cent for radiation.

Although numbers in the different age and treatment groups were small and differences not statistically significant, 55 patients aged 65 years and over treated by surgery did not do as well as almost the same number treated by surgery and radiation and hardly better than those treated by radiation alone (Table 4).

#### Social class and survival in cancer of the cervix

The question of a possible relationship between the social class of patients with cervical cancer and their prognosis is important for two reasons. First, as shown in Table 5, taken from the Registrar General's Decennial Supplement for England and Wales for 1951\*, death rates due to

\* The Registrar General's Decennial Supplement, England and Wales, 1951, Occupational Mortality, Part II, Vol. 2, Tables. H.M.S.O. 1958.

	Stage	All forms	Surgery	Radiation	Surgery and radiation	No known form of treatment
		2 s.e.	2 s.e.	2 s.e.	2 s.e.	2 s.e.
	ALL Localised Not localised	46.6 ± 5.9	56.9 ± 18.2	40.4 ± 7.5	58.3 ± 11.4	27.4 ± 38.2 (6 cases)
0-34	Localised	57.5 ± 7.3	68.9 ± 21.4	48.5 ± 9.6	70.1 ± 12.3	100.0 ± 00.0 (2 cases)
	L Not localised	26.4 ± 8.9	35.6 ± 29.5	26.7 ± 11.1	25.4 ± 19.6	0.0 ± 00.0 (4 cases)
	ALL Localised Not localised	42.9 ± 3.4	67.6 ± 10.6	35.7 ± 4.1	58.8 ± 7.3	5.0 ± 9.6
35-44 .	Localised	58.2 ± 4.5	79.8 ± 10.6	50.6 ± 6.0	64.4 ± 8.1	$0.0 \pm 0.0 (1 \text{ case})$
	L Not localised	22.4 ± 4.4	30.4 ± 20.7	$20.3 \pm 4.9$	41.0 ± 14.8	5.2 ± 10.0
	ALL Localised Not localised	42.1 ± 2.6	66.0 ± 9.9	40.1 ± 2.9	54.1 ± 7.2	6.0 ± 5.7
45-54	{ Localised	59.9 ± 3.7	86.3 ± 9.3	55.7 ± 4.4	65.7 ± 8.5	34.5 ± 32.5
	( Not localised	24.5 ± 3.1	25.0 ± 15.4	26.1 ± 3.6	31.3 ± 11.4	1.8 ± 3.6
	ALL Localised Not localised	43.1 ± 2.6	63.1 ± 12.1	44.3 ± 3.0	52.2 ± 8.9	0.0 ± 0.0
55-64 <	Localised	61.5 ± 3.8	76.5 ± 13.8	60.6 ± 4.2	62.4 ± 11.1	0.0 ± 0.0
	( Not localised	25.3 ± 3.2	37.1 ± 20.0	27.8 ± 3.7	35.2 ± 13.6	0.0 ± 0.0
	ALL Localised Not localised	38.0 ± 3.3	44.2 ± 16.4	42.1 ± 3.8	54.1 ± 17.4	3.4 ± 3.4
65-98 <	Localised	57.0 ± 5.4	59.3 ± 24.5	57.1 ± 5.8	76.6 ± 21.8	11.2 ± 21.5
	L Not localised	23.3 ± 3.7	28.5 ± 20.4	$28.6 \pm 4.6$	18.9 ± 20.1	2.8 ± 3.2
	ALL 1948-49	37.6 ± 1.4	53.9 ± 7.5	39.1 ± 1.5	47.1 ± 4.8	$1.7 \pm 1.4$
	1952-53	42.0 ± 1.4	62.0 ± 5.7	41.2 ± 1.6	55.6 ± 4.0	3.4 ± 2.1
	Localised		A PARTY A			
All	1948-49	55.1 ± 2.1	56.9 ± 10.5	EE 7 L O A	EE O L C O	10 0 1 10 0
Ages <	1948-49	$59.4 \pm 2.0$	$50.9 \pm 10.5$ 77.9 ± 6.2	$55.3 \pm 2.4$ 56.3 ± 2.4	$55.9 \pm 6.2$ $65.8 \pm 4.7$	$12.6 \pm 16.8$ $22.7 \pm 17.9$
11800		00.11.0.0		00.0 1 A.4	00.0 I 4.7	W. 1 I 11.9
	Not localised 1948-49	21.8 ± 1.6	7774470	04 E + 4 0		
	1948-49	$21.8 \pm 1.6$ $24.2 \pm 1.7$	$33.3 \pm 13.0$ $30.5 \pm 9.0$	$24.5 \pm 1.9$ $26.3 \pm 2.0$	$27.4 \pm 7.6$ $32.9 \pm 6.7$	$1.1 \pm 1.1$ $1.8 \pm 1.6$

Table 4.	Cancer of the cerv	ix (confirmed	and not confirmed).
	survival rates by	age, stage and	form of treatment.

1952-53 registrations. Age-corrected 5-year

Table 5.	Cancer	of t	he	cervix	-	mortalit	y b	y soci	al	class,	1949-53
----------	--------	------	----	--------	---	----------	-----	--------	----	--------	---------

Social Class	Standar Mortali 20 <del>-</del> 64 y	ty Rate	Proportional Mortality Rate 65 years and over		
DALCIIONS T	Married women	Single women	Married women	Single women	
I Professional, etc. occupations II Intermediate occupations III Skilled occupations IV Partly skilled occupations V Unskilled occupations	64 75 98 105 134	(40) 61 87 121 115	<i>81</i> 89 100 97 125	(167) 111 98 98 (175)	

Note: Rates in italics are based on less than 50 deaths. Rates in brackets are based on less than 10 deaths.

this disease are very much higher in the lower social classes, this trend being clearly evident in married females of all age-groups and in single females under 65 years of age. This raises the question whether this social class gradient in the death rate is due to a higher incidence or poorer survival in the lower social classes. Secondly, it has been found that the prognosis of cases with cancer of the cervix is much better in the U.S.A. than in England and Wales; for example, the crude five-year survival rates in 1950-54 was 52.3 per cent in the Connecticut Cancer Registry figures as against 38.1 per cent here in 1952-53, and it has been suggested that this may be accounted for by significant social class differences in the survival figures of England and Wales\*. However, this comparison must be treated with reserve because it compares the results obtained in two entirely different geographical areas.

For the year 1949, occupation was included in the information received by the cancer registry. Although many of the notifications described the patient's occupation simply as "housewife", 1,008 registrations of cervical cancer received in that year gave either the husband's or the patient's occupation. These were separated into social class categories using the same classification of occupations as the 1951 *Decennial Supplement*, and the survival experience of these patients is shown in Table 6 as both crude and age-corrected rates. Social Classes I and II have been combined because of small numbers. The results show no well-defined effect of social class on the survival of women with localised disease. Amongst the remainder, however, the prognosis shows a clear social class gradient, but in the reverse direction to what might have been expected, in that the women of Social Class V fared better than those of Classes I and II. The survival of all social classes and stages combined, is similar to that of England and Wales in 1948-49 (Table 4).

\* Int. Symp. End Results of Cancer Therapy, NCI Monograph No. 15. Bethesda, 1964.

	Localised disease 5-year survival			and the second se	All others 5-year survival 5			All stag year surv	Percentage with	
Social Class	Number	Crude rate	Age- corrected rate	Number	Crude rate	Age- corrected rate	Number	Crude rate	Age- corrected rate	localised disease
I and II	65	57.65	62.06	69	17.33	19.07	134	36.76	40.02	48.5
III	220	56.19	59.05	259	20.08	21.70	479	36.63	39.08	45.9
IV	89	59.55	62.73	104	23.08	24.70	193	39.90	42.39	46.1
V	88	52.27	55.52	114	25.44	26.96	202	37.13	39.39	43.6
All Social Classes	462	56.28	59.49	546	21.42	23.06	1,008	37.37	39.90	45.8

Table 6.Cancer of the cervix, 1949 registrations.5-year survival rates (crude and age-corrected) and<br/>percentage with localised disease by social class.

#### CARCINOMA OF THE UTERINE CORPUS

In 1952-53, 1,896 cases of carcinoma of the uterine body were notified, 1,761 (93 per cent) of these having had histological confirmation of the tumour.

Nearly two-thirds (64 per cent) of all cases (confirmed or unconfirmed) were considered to have clinically localised disease, that is without evidence of spread to adjacent or distant viscera. The age distribution and proportion with localised disease in each age-group was as follows:

Age-group	Per cent of cases	Per cent with localised growths			
0-44	6	69			
45-54	23	67			
55-64	39	67			
65-98	32	57			
All ages	100 (1,896)	64			

These figures indicate that patients who were 65 years and over were more likely to have advanced disease than younger patients.

#### Choice of treatment

Table 7 shows that 46 per cent of patients were treated by surgery, 24 per cent by surgery and radiation therapy, and 23 per cent by radiation therapy alone. The last includes a combined attack on the tumour by intra-uterine radium and external irradiation.

Table 7.	Numbers and percentages of cases of carcinoma of the uterine body	
	by stage and form of treatment	

Clinical		All atments	Sı	irgery	11 10 1 W/ 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	gery and liation	Rad	diation	No known treatment	
Stage	No.	Per cent	No.	Per cent	No.	Per cent	No.	Per cent	No.	Per cent
Localised	1,212	100	650	54	303	25	236	19	23	2
Not Localised	684	100	217	32	147	21	202	30	116	17
All Stages	1,896	100	867	46	450	24	438	23	139	7

2 cases only received chemo-hormone treatment.

#### Results

The five-year age-corrected survival of 67 per cent was in keeping with the comparatively good prognosis known to be associated with malignant disease of the uterine body. This figure increased to 79 per cent if cases with localised disease only were considered. The following were the results for the different age-groups:


Age-group	All stages	Localised cases	Not localised cases		
5 .0.4.4	% 2 s.e.	% 2 s.e.	% 2 s.e.		
0-44	76.5 ± 8.4	97.2 ± 4.7	30.7 ± 16.2		
45-54	76.4 ± 4.3	85.8 ± 4.5	57.4 ± 8.5		
55-64	69.2 ± 3.8	79.8 ± 4.2	47.6 ± 6.9		
65-98	50,8 ± 5.3	66.4 ± 7.1	28.9 ± 7.0		
All ages	66.5 ± 2.5	79.3 ± 2.9	43.0 ± 4.3		

The poorer age-corrected survival of patients 65 years of age and over is shown separately in the two stages of spread and is in keeping with the suggestion in the *Supplement on Cancer* to the *Registrar General's Statistical Review of England and Wales for 1953* that the malignancy of the tumour tended to increase with age. The extremely favourable survival of patients under 45 years of age with localised disease is noteworthy; 70 of the 73 surviving five years after treatment. In all but five the diagnosis had been confirmed by histology. However, Willis\* has pointed out the difficulty of distinguishing in a minority of histological sections between atypical hyperplasia and commencing carcinoma.

#### Results in different forms of treatment

From Table 8 it can be seen that the results for all stages and ages combined were slightly better after surgery (five-year age-corrected survival of 80 per cent) than after surgery combined with radiation therapy (corresponding survival figure 76 per cent). Selection of cases may have been responsible for this as well as for the comparatively poor results obtained after radiation therapy alone. It is interesting that the fiveyear age-corrected survival of 23 patients (18 confirmed by histology) with localised disease and subjected to no known treatment was 69 per cent, compared with 56 per cent for early cases treated by radiation therapy. However, the difference was not statistically significant, and when all stages are considered the corresponding survival figure for patients given no known treatment was only 13 per cent.

Table 8 also shows results for different forms of treatment in various age-groups. The figures suggest that in elderly patients, surgery with radiation therapy is the best method in localised cases. Again the finding on which this is based is not significant and may be the result of random variation.



\* Willis, R. A. (1953) Pathology of Tumours. Butterworth and Co. Ltd., London.

## Table 8. Five-year age-corrected survival percentages of carcinoma of the uterine body by age and treatment category (confirmed and not confirmed)

Age-group Clinical stage		All treatments		Surgery			Surger radia	Radiation	
Ta	Localised	% 2 97.2 ±	s.e. 4.7		2 s.e. ± 6.2	(22	% 100.0 cases,	2 s.e. ± 0 no deaths)	% 2 s.e. 81.2 ± 36.3 (5 cases)
0-44	Not localised	30.7 ±	16.2	60.9 : (10 ca			16.8 cases,	± 30.8 5 deaths)	20.2 ± 25.6 (10 cases)
45-54	Localised	85.8 ±	4.5	91.9 :	£ 5.0		83.5	± 8.3	62.7 ± 17.6
	Not localised	57.4 ±	8.5	69.4	± 13.1		74.8	± 13.5	37.0 ± 18.7
1.2003.00 00	Localised	79.8 ±	4.2	86.4	£ 5.1		78.8	± 8.3	59.9 ± 11.6
55-64	Not localised	47.6 ±	6.9	70.5	± 11.4		61.9	± 13.6	29.3 ± 11.8
Contraction Contraction	Localised	66.4 ±	7.1	73.3	± 10.0		80.8	± 15.6	49.0 ± 12.5
65-98	Not localised	28.9 ±	: 7.0	49.7	± 15.3	0.00	46.4	± 21.3	22.4 ± 10.6
	Localised	79.3 ±	: 2.9	85.8	± 3.6		82.4	± 5.2	56.4 ± 7.8
ALL AGES	Not localised	43.0 ±	4.3	64.0	± 7.6		61.3	± 9.0	27.2 ± 7.1
	All stages combined	66.5 ±	2.5	80.4	± 3.3		75.6	± 4.7	43.1 ± 5.5

Comparing the survival of 1952-53 registrations with that of patients registered in 1948-49, it can be seen from the following figures (Table 9) that there was improvement in the later period after surgery, surgery combined with radiation therapy, and after radiation therapy alone.

## Table 9. Five-year age-corrected survival percentages of carcinoma of the uterine body by clinical stage and treatment category

Period	Period Clinical stage		Surgery	Surgery and radiation	Radiation
1948-49	Localised	398. shade 1	81.6 ± 6.0	% 2 s.e. 75.2 ± 9.0	50.3 ± 8.2
and the second se	Not localised	32.2 ± 4.8	57.8 ± 11.5	54.2 ± 13.1	23.8 ± 6.8
1952-53	Localised	79.3 ± 2.9	85.8 ± 3.6	82.4 ± 5.2	56.4 ± 7.8
199%-99	Not localised	43.0 ± 4.3	64.0 ± 7.6	61.3 ± 9.0	27.2 ± 7.1

The improvement in the survival of the 1952-53 registrations for all treatments combined is statistically significant for localised and advanced cases separately (P<.01). It should be pointed out that coverage was poorer before 1950, most of the notifications being from radiation centres and therefore probably of more advanced cases. However, this would not apply to the improvement after treatment by radiation or radiation combined with surgery.

able 8. millionismer age-corrected attered attered arrentings of confidence of the

2011年1月4日

#### CANCER OF THE PROSTATE

In 1952-53, 2,398 cases (confirmed and unconfirmed by histology) of cancer of the prostate were registered in England and Wales, of which 59 per cent were 70 years of age or over. Forty-two per cent of this older age-group were considered to have clinically localised disease, i.e. no evidence was found of spread to tissues surrounding the prostate or of metastases, and 40 per cent in the group under 70 years of age.

#### Choice of treatment

Seventy per cent of patients with localised disease were treated by surgery and the majority of the remainder by chemotherapy or hormones. This last group is not further subdivided but it is doubtful whether other forms of treatment besides administration of oestrogens and endocrine gland ablation were used in significant numbers of cases.

In patients where the disease was not considered clinically to be localised, only 34 per cent were subjected to surgery and 41 per cent to chemotherapy or hormone treatment, while 7 per cent were given radiotherapy.

It is more than likely that most patients who were surgically treated were subsequently given hormone therapy.

#### End results

Twenty-two per cent of patients survived five years, the age-corrected survival rate (allowing for the greater incidence of competing causes of death in older patients) being 34 per cent. In spite of the same correction for age, the results in those 70 years of age and over were poorer, particularly for cases with localised disease, as the following figures show:-

Age-group	All stages	Localised	Not localised
0-69 70-98	% 2 s.e. 38.9 ± 3.6 29.7 ± 3.6	% 2 s.e. 64.9 ± 6.2 44.4 ± 6.5	% 2 s.e. 21.9 ± 3.8 18.8 ± 3.9

Table 10. Five-year age-corrected survival percentages of cancer of the prostate by age, stage and form of treatment

Stage	Age- Group	Surgery	Chemo-hormones	Radiation
Localised	0-69 70-98	% 2 s.e. (268) 61.7 ± 7.6 (431) 47.5 ± 7.9	% 2 s.e. ( 93) 73.9 ± 12.4 (135) 42.0 ± 13.2	% 2 s.e. ( 7) 86.3 ± 41.2 ( 7) 30.7 ± 56.9
Not Localised	0-69 70-98	(177) 26.8 ± 7.7 (296) 22.1 ± 7.1	(248) 28.3 ± 6.5 (324) 21.2 ± 6.6	( 61) 9.5 ± 8.2 ( 37) 13.4 ± 14.9

(numbers of cases shown in brackets)

Turning to the results for different methods of treatment, it is seen in Table 10 that, contrary to the fact that it might be expected that surgery was reserved for cases with more favourable outlook, treatment by chemo-hormones was followed by a better age-adjusted 5-year survival rate than surgery in localised cases under 70 years of age, though the difference was not statistically significant. Diagram 2 shows that this was mainly due to a highly significant difference in survival in the first year after treatment ( $P \le .001$ ) in favour of patients who had been treated by chemo-hormones. This raises the question as to whether post-operative deaths might have affected the survival after surgery.

For patients registered in 1948-49, ten-year age-corrected survival rates are available and comparison of the results after these two forms of treatment in patients of the corresponding age- and stage-group is as follows:-

	Surgery Chemo-hormones		
5-year age-corrected survival 10-year age-corrected survival	% 2 s.e. (124) 68.3 ± 11.0 (124) 41.3 ± 13.1	% 2 s.e. (68) 66.0 ± 14.6 (68) 28.6 ± 15.0	

#### (numbers of cases shown in brackets)

It can be seen that the survival was similar for the two forms of treatment in the first five-year period, but at the end of 10 years the figures suggested that the prognosis was better after surgery, although this difference was not statistically significant and possibly due to random fluctuation. Diagram 2 shows separately the survival curves of the younger patients with early prostatic cancer registered in 1948-49 after these two forms of treatment. Again the larger mortality in the first year after surgery is evident, as well as the tendency for the survival curve in prostatic cancer to maintain its downward slope thus indicating that in this type of malignant disease the age-corrected annual death rate remains high for an unusually long period after treatment. For this reason both 5-year and 10-year survival rates should be considered in comparing results in prostatic cancer.

Comparison of the results in non-localised cases after radiotherapy with those after chemo-hormones shows consistently better results after the latter form of treatment. (Table 11).


Five-year age-corrected survival percentages among non-localised

cases of cancer of the prostate for two periods by age and form of treatment


Table II

Age-group	Period	Chemo-hormones	Radiation therapy	
0-69	1948-49 1952-53	% 2 s.e. (194) 24.7 ± 7.1 (248) 28.3 ± 6.5	% 2 s.e. (54) 10.9 ± 9.3 (61) 9.5 ± 8.2	
70-98	19 <b>48-</b> 49 1952-53	(179) 20.8 ± 8.7 (324) 21.2 ± 6.6	(18) 9.3 ± 18.1 (37) 13.4 ± 14.9	

(numbers of cases shown in brackets)



#### LOCALISED CANCER OF PROSTATE, AGE-CORRECTED SURVIVAL PERCENTAGES, UNDER 70 YEARS OF AGE



nd rozalis of treatment (histologically confirmed cases, 1962-63

situp-live per cent of cases with seminors and 55 per cent with termin ere alive alter five years, the age-corrected figures for this period of writed being 60 per cent and 55 per cent respectively.

## MALIGNANT DISEASE OF THE TESTIS

In 1952-53 there were 386 registrations of malignant testicular tumours, comprising 221 seminomas (57.2 per cent), 160 teratomas (41.5 per cent) and 5 other cases (1.3 per cent) in which the histology did not conform with either of these groups. At least 94 per cent of the seminomas and teratomas separately were confirmed by histology. The age distribution in three broad age-groups of those patients who had microscopic confirmation was as follows:-

Age	Semir	10ma (208	cases)	Teratoma (152 cas	ses)
i	annon de carene Pro-	per cen	t	per cent	
0-3 35-4 45-9	34 14 08	29 38 33		55 24 21	
A11 a	ages	100	1 14.0 ± 11.0	100	-84 61

The typical young age distribution shown for both types of tumour was particularly marked in the case of teratoma, where over half the registrations were of patients under 34 years of age.

#### Stage

In just over 60 per cent of patients with either type of tumour the growth was found to be localised - that is, there was no clinical evidence of spread from the testis to adjacent tissues, lymph nodes or other organs. The proportion of localised tumours in cases with histological confirmation in three age-groups was as follows:-

Age	Seminoma	Teratoma
nen alle (30. >	per cent	per cent
0-34 35-44 45-98	66 59 59	55 73 66
All ages	61	62

#### Choice of treatment (cases confirmed by histology)

As more than 94 per cent of both the seminomas and teratomas were confirmed by histology, little will be lost by excluding the unconfirmed cases from the discussion which follows.

Choice of treatment was similar for both teratomas and seminomas, 74 per cent of the former and 80 per cent of the latter undergoing surgery combined with radiation, the remainder surgery (mainly) or radiation only.

## End results of treatment (histologically confirmed cases, 1952-53 registrations)

Sixty-five per cent of cases with seminoma and 53 per cent with teratoma were alive after five years, the age-corrected figures for this period of survival being 69 per cent and 55 per cent respectively.

Table 12 shows that the prognosis was affected by the clinical stage of the growth, the five-year age-corrected survival for patients with localised teratomas being 72 per cent and 84 per cent for cases with early seminoma.

#### Survival in various age-groups

From the following figures it can be seen that prognosis was also better in patients who were 45 years of age and over compared with younger patients. This remains true even when crude survival figures are used which do not correct for the higher incidence of competing causes of death in older patients.

	Seminoma			Teratoma		
Age	No. of cases	Crude survival percentages	Age-corrected survival per- centages and 2 s.e.	No. of cases	Crude survival percentages	Age-corrected survival per- centages and 2 s.e.
0-34 35-44 45-98	61 78 69	61.8 64.9 68.1	$62.3 \pm 12.6$ $66.1 \pm 11.0$ $77.8 \pm 12.8$	83 37 32	51.8 45.9 62.5	$52.2 \pm 11.0$ 46.6 ± 16.6 71.5 ± 19.5

With regard to results after different forms of treatment it can be seen from the figures for the 1952-53 registrations in Table 12 that for all stages combined the survival after surgery was poorer than after surgery with radiation therapy.

#### Trends in survival results, 1948-49 and 1952-53

Comparison of results obtained in cases of seminoma treated in 1952-53 with the results in 1948-49 registrations showed a significant improvement in the survival of patients of all stages combined treated by surgery combined with radiation in the later period ( $P \le .01$ ). Only 7 cases in 1948-49 and 15 in 1952-53 with histological confirmation were treated by radiation alone, but if cases without biopsy are included, the improvement in results after this form of treatment was also significant ( $P \le .05$ ). This may be due to the more widespread use of megavoltage radiotherapy in the later period, as high energy machines are particularly advantageous in radiation of deep seated areas of the body such as the lymph drainage system of the testis. It is note-worthy that the improvement in the case of teratoma, which is less responsive than seminoma to radiation therapy, is much less spectacular.

Choice of ireathent (cases danfined by histolocy) he note that 94 per coult of out the scalations sid terators wert constrained by histology, little will be Load by cacibding the shortlined researing the theorem. Which holicas Chaice of treathent was ditting for hoth terators and scalations. '4 on the of the fermer and so per own; of the latter moderating caugery tothics with restaring, the revealeder surgery (salaty) or restaring only.

28

RENDS IN THE PROSEDSTA OF

"Note 13 shows the numbers of pathwork will through Theprovic on bloid isukasnia resistered in 1046-00 and 1057-05 and the proposition wated by radiation, these-bostones and resistion will show down

13. Revers of patients with chronic lymphotic and symbolic deukarets and proportions by method of transmitt

#### The all that there it a state of the it what there shows a second the second state of the second state of

totota de la companya de la companya

testing di testi di testi ante se car i trenigit antella tra di treni della sobrita di treni testi della di testi della tren para della tren para della della di treni della sobrita di treni di testi della della segli della treni della di treni della poder di tesso "to rescuere edi lognico (le menero) all'estito moreno escare esti esti della di treni della testi della di tesso "to rescuere edi lognico (le menero) all'estito moreno esti esti della di treni della della

		AN CONTRACTOR

tin transfer in constant after if thereas from a forestern in the test of the test of all after and all after at a constant of the test of all after an are all after and a constant of the test of test of the test of test o

#### reside at any series resulting " series and series and

""

#### TRENDS IN THE PROGNOSIS OF CHRONIC LEUKAEMIA

Table 13 shows the numbers of patients with chronic lymphatic and myeloid leukaemia registered in 1948-49 and 1952-53 and the proportions treated by radiation, chemo-hormones and radiation with chemo-hormones.

## Table 13. Numbers of patients with chronic lymphatic and myeloid leukaemia and proportions by method of treatment

## Chronic lymphatic leukaemia

#### Males

Nu	mber	Contraction of the second second		Construction of the
tion of treatment	uidei	Radiation	Radiation and chemo-hormones	Chemo-hormones only
	233	66	6	3
1952-53 registrations	385	52	14	8

1948-49 registrations 1952-53 registrations		63 54	51.405402 8 8	2 12	
	A REAL PROPERTY OF THE REAL PR				

#### Chronic myeloid leukaemia

Males

	and descent states in the	Per cent treated by			
	Number	Radiation	Radiation and chemo-hormones	Chemo-hormones only	
1948-49 registrations 1952-53 registrations	137 223	66 44	11 19	2 9	
Females	5.9 Å.		10 10 10 t	-9961 1968-	
1948-49 registrations 1952-53 registrations	174 265	67 52	12 19	3 9	
				1952-1 1952-1 1962-1 1952-1	

The figures refer to the treatment used initially and give no indication of therapeutic methods employed later on in the course of the disease. It would be fair to say, however, that patients registered in 1952-53 were subject to improved methods of radiotherapy and supportive treatment and many more eventually received chemo-therapy than the small percentage appearing in Table 13. This is much less likely to be true of those registered in 1948-49.

#### Results

The two- and five-year age-corrected survival of patients registered with chronic lymphatic and chronic myeloid leukaemia in 1948-49 and 1952-53 are presented in Table 14. The results are also shown for patients undergoing radiotherapy and those given no initial treatment, the numbers in these categories being large enough for analysis.

Table 14. Chronic lymphatic and chronic myeloid leukaemia, two- and fiveyear age-corrected survival percentages


(± 2 standard errors shown for five-year survival)

(a) Males


Survival period	All cases	Cases treated by radiation	Cases with no known treatment
In a sign of the second s	Chronic lymphat	ic	1948-49 registrat
2-years 1948-49	34.3	38.7	24.9
1952-53	39.5	43.4	31.6
5-years 1948-49	$8.2 \pm 3.9$	$9.2 \pm 5.1$	$4.3 \pm 6.0$
1952-53	$18.5 \pm 4.5$	$19.5 \pm 6.4$	22.2 ± 10.2
	Chronic myeloid		1848-49 registrati
2-years 1948-49	35.0	34.4	12.1
1952-53	30.5	35.2	10.6
5-years 1948-49	$5.7 \pm 4.2$	$4.9 \pm 4.8$	$\begin{array}{c} 0.0 \pm 0.0 \\ 0.0 \pm 0.0 \end{array}$
1952-53	7.0 $\pm 3.6$	$6.9 \pm 5.4$	
(b) Females	Par and	T	
Survival period	All cases	Cases treated by radiation	Cases with no known treatment
	Chronic lymphat	ic	Inertainer Ga-SaGi
2-years 1948-49	43.1	52.1	21.2
1952-53	43.8	49.9	26.0
5-years 1948-49	10.6 ± 5.4	$13.0 \pm 7.4$	6.8 ± 9.2
1952-53	25.5 ± 6.4	23.2 ± 8.5	22.6 ± 12.7
	Chronic myeloid		
2-years 1948-49	37.0	41.8	18.0
1952-53	34.7	39.7	17.8
5-years 1948-49	$3.1 \pm 2.7$	$3.7 \pm 3.6$	$0.0 \pm 0.0$
1952-53	$8.8 \pm 3.7$	$8.9 \pm 5.1$	2.5 ± 4.9

Diagram 3


CHRONIC LYMPHATIC LEUKAEMIA. COMPARISON OF SURVIVAL PERCENTAGES (AGE CORRECTED) OF 1952-53 REGISTRATIONS WITH THOSE OF 1948-49








An interesting finding of the analyses is the statistically significant improvement (P  $\leq$  .05) in the five-year survival for chronic lymphatic leukaemia of patients registered in 1952-53 compared to those registered before 1950 shown in males and females separately. This is also apparent in male cases treated initially by radiotherapy, as well as those of either sex for whom "no known treatment" was recorded. This improvement is far less evident in the two-year survival of these patients (Diagram 3), and does not seem, therefore, to be the result of changes in the treatment given soon after diagnosis or to the registration of cases at an earlier clinical stage in 1952-53, though this may have happened to some extent. On the other hand, chemotherapy or steroids given later in the course of the disease, as well as improved forms of radiotherapy and supportive treatment. may have been responsible for the better survival experience of the 1952-53 registrations. This trend should be watched for further evidence of improvement, which would confirm the impressions of many clinicians that modern methods of treatment are prolonging the life of the average sufferer.





## Appendix Table A.

Registrations of newly diagnosed cases of cancer among males by site and age.

England and Wales, 1961

	TOD No. and alto descentation										Ag	e-grouj	p							Age	A11
	ICD No. and site description	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85 & over	not stated	ages
140 141 142 143 144	Lip Tongue Salivary gland Floor of mouth Other mouth (specified and	- 1	1111	2 -	- - 4 -	- 1 5 1	2 1 17 -	2391	6	15 10 14 1	27 9 18 5	45 27 22 5		60 41 19 21	57 43 22 17	84 51 18 15	66 59 9 21	44 39 8 14	28 23 4 8	1 - - -	508 338 205 119
145 146 147 148 150	unspecified) Oral mesopharynx Nasopharynx Hypopharynx Pharynx (unspecified) Oesophagus		1311	- - - - - - - - - - - - - - - - - - -	1 4 1 1 1	- 1 1 -	1 1 2 1 1 1	2 1 1 1 4	1 1 5 1 - 4	5 2 7 1 3 13	10 3 8 4 2 45	12 12 13 16 5 73	20 31 12 29 13 114	35 32 14 46 12 168	46 34 9 38 14 161	45 26 9 35 12 180	45 27 5 39 14 152	31 16 3 14 12 101	14 10 1 9 3 44	- - 1 - 1	266 196 102 236 92 1,062
151 152 153 154 155	Stomach Small intestine, including duodenum Large intestine, except rectum Rectum Biliary passages and liver	1 	1 1 1 1	- - 1	- 1 2 -	2 - 8 5	7 - 10 5	22 1 28 17	60 4 53 27	116 6 65 65	272 16 157 121	503 17 240 244	764 19 357 402	926 23 480 501	909 15 536 526	900 14 557 517	631 5 464 443	310 3 304 270	111 	3 - 1 2	5,537 124 3,389 3,257
	(specified primary) Liver (secondary and unspecified) Pancreas Peritoneum Unspecified digestive organs Nose, nasal cavities, etc.	6	11111	1 - 1 -		- 1 1	NN1211	71161	8 5 15 4 1 3	15 5 36 10 - 6	24 9 73 8 - 12	48 30 129 11 - 14	73 49 206 16 2 23	91 57 237 13 - 35	107 63 273 11 4 26	77 56 241 8 - 24	49 19 196 4 1 20	35 14 105 7 _ 11	17 8 42 1 - 5		561 319 1,559 104 8 179
161 162 163	Larynx Lung (specified primary), bronchus and trachea Lung (unspecified primary or	- 1		1 1	- 2	1 9	3 11	3 54	11 173	28 337	49 816	85 1,907	142 2,970	149 3,421	146 2,899	111 2,092	72 1,078	34 353	16 100	2 15	852 16,238
	secondary) Mediastinum and thoracic organs (secondary) Breast Prostate	1 2 1 2	- 1	- 1			1 1 20 1	- 1 1 -	1 1 3	- 236	- 5 10 17	2 8 9 68	4 28 25 188	1 21 19 355	3 19 17 603	- 17 22 896	3 11 14 920	- 6 10 625	- 4 1 306	- - 4	14 129 136 3,990
178 178 179.0 179.1 179.7-9	Testis - seminoma Testis - other types of growth Penis Scrotum Other and unspecified male genital	12	2 1 -	1111	2 11 -	11 30 -	31 32 2	51 35 4 1	42 20 4 -	40 14 12 2	26 9 12 5	17 6 24 4	16 5 24 17	10 3 31 11	4 22 42 9	3 4 23 6	6 1 35 6	1 3 24 3	- - 12 4	1	264 178 249 68
180 181 190 191	organs Kidney Bladder and other urinary organs Melanoma of skin Rodent ulcer	- 23 2 1 -	1 4 - 1 -	1 - 1 2 -		- 5 4 4	- 4 11 9 12	7 13	34	- 32 51 16 215	1 64 117 23 354	- 112 208 22 485	335 26	473 23	1 116 518 14 584	- 93 504 18 577	- 74 385 17 447	- 42 236 10 326	9 96 95	- 2 6 - 29	7 869 2,988 224 4,646

191	Other malignant neoplasm of skin	-	-	-	-	3	1	7	20	46	71 13	113 11	138	177	221	220 10	240	172	127	5 1	1,561
192 193.0	Eye Brain - malignant neoplasm, other than glioma	21 3	22	-	4	1	25	4	3	5	15	11	18 8	12	13 3	4	1	4		-	60
	Brain - gliomas (not specified as benign)	27	18	25	10	14	17	23	41	55	77	121	137	123	57	21	5	4	-	1	776
	Brain - benign neoplasm Other parts of nervous system -	2	5	5	6	8	8	8	15	7	10	15	29	25	25	9	1	1	-	-	179
	any type of neoplasm	7	3	7	8	6	5	13	10	14	15	29	22	16	9	8	4	1	1	-	111
194 195.0	Suprarenal gland - malignant	-	-	1	1	1	1	7	1	4	6	11 2	10	15 3	14 3	18 5	14	6 2	1	-	32
	neoplasm Suprarenal gland - benign neoplasm	71	21	21	1	1 1	1	1	1	-	1 -	~	1	1	-	-	-	2 1	-	-	3
	Other endocrine glands - malignant neoplasm Other endocrine glands - benign	-	-	2	1	4	1	6	1	2	3	4	2	5	3	-	-	-	-	-	34
196	neoplasm Bone	3	47	- 11	- 33	2 11	- 8	5 12	777	9	10 15	5 20	9 27	5 30	3 24	1 23	- 19	- 6	- 6	1	63 272
197 198	Connective tissue Lymph nodes (secondary and	6	-	3	9	11	9	10	13	13	17	26	22	37	25	21	16	11	3	-	252
199	unspecified) Other and unspecified sites	1 2	1 1	- 2	1 1	- 2	3 6	1 6	2 14	3 27	13 41	24 78	31 134	28 150	28 169	27 134	21 101	9 52	7 21	1	199 941
200.0		-	3	9	14	6	14	12	17	13	22	25	41 50	37 57	25 45	29 31	13 28	4 14	3 1	1 1	287 386
201	Lymphosarcoma Hodgkin's Disease	11 1	9 7	8 22	12 20	5 40	9 60	10 44	15 38	16 39	27 53	38 51	52	46	40	26	13	9	4	-	567
	Other forms of lymphoma (reticulosis) Multiple myeloma (plasmocytoma)	1	1	2	3	7	3	10	6	9 18	13 26	12 23	24 46	19 59	17 34	11 46	5 20	4 11	5 5	-	152 299
204.3 part	Lymphatic leukaemia - acute Lymphatic leukaemia - chronic and	48	9	11	13	5	5	7	5	5	6	8	8	9	17	9	7	5	-	-	177
~~~~~	unspecified	2	1	-	-	1	-	2	4	11	10	16	40	45	56	55	61	27	7	-	338
	Myeloid leukaemia - acute Myeloid leukaemia - chronic and	16	9	18	10	9	8	17	23	18	18	23	22	25	38	24	11	18	4	1	312
204.2 part	unspecified Monocytic leukaemia - acute	4	1	2 -	2 3	7 4	6 3	8	6 5	13 3	16 4	22 2	28 5	20 10	19 5	24 11	20 7	14	2 1	1 1	214 67
	Monocytic leukaemia - chronic and unspecified	1			-	-	-	1	-	2	1	1	3	3	1	5	-	1	1	-	17
	Leukaemia - cell type not stated - acute	16	9	5	3	1	3	3	1	3	5	3	3	6	7	5	6	1	2	-	81
	Leukaemia - other stated and unstated cell type Other lymphoid tissue and mycosis	-	-	•	-	1	-	-	1	-	3	2	4	5	5	-	2	2	-	-	25
200.2 & 205	fungoides	-	1		70	3	3	1	2	6	4	8	8	7	10	4	2	90 -	2	and the second	61
	Premalignant conditions - all sites Doubtful malignancy - all sites	- 2		1 1	1 1	1 1	11	11	1 1	- 2	1	5	5 2	4 2	6 1	4 2	4 1	1			30 14
	All sites of pure and sha	233	107	150	185	248	354	546	946	1,512	2,837	5,127	7,653	9,134	8,813	8,022	5,967	3,393	1,521	81	56,829

36

## Appendix Table B. Registrations of newly diagnosed cases of cancer among females by site and age

	and the second states and the								Ag	ge-grou	ıp	·								Age	A11
	ICD No. and site description	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85 & over	not stated	ages
	Lip	-	-	-	-	-	-	-	1	- 4	4	4	5 8	3	10	8	9	8 19	6	-	58
141 142	Tongue Salivary gland	-	-	-		-	1	-	1		6	11	8	20	20	31	33		12	-	166
142	Floor of mouth	-	-	5	6	5	14	22	25	12	26	26	29	26	13	24	12	14	10	1	270
143	STREET STORE STREET S	-		-	-	-	-	-	1	-	-	9	5	5	5	9	11	7	2	-	54
	unspecified)	_			1	1	1	3	4	Б	4	14	14	19	27	34	20	17	-	-	1.00
145	Oral mesopharynx	-	-	-	-	-	-	-	1	4	4	7	10		7	54 9	20	13 8	8 8	-	168 74
146	Nasopharynx	-	-	-	2	-	-	-	-	-	4	3	5	12	4	2	4	3	0	-	39
147	Hypopharynx	-	-	-	-	-	-	4	-3	11	16	22	26	38	38	23	25	14	2	1	223
148	Pharynx (unspecified)	-	-	-	-	-	-	1	1	2	6	5	10	8	7	11	6	6	2	-	65
150	Oesophagus	-	-	-	-	-	-	7	9	18	24	68	62	86	127	124	131	97	41	2	796
151	Stomach	_	-	_	_	2	13	14	38	60	108	205	323	442	634	691	606	392	179	7	0 740
152	Small intestine, including					~	10	7.4	00	00	100	200	020	446	034	OAT	000	292	1.1.9	3	3,710
	duodenum	-	1	-	-	-	-	1	6	Б	Б	8	14	15	13	9	9	6	1	_	93
153	Large intestine, except rectum	-	-	4	9	12	16	33	67	112	221	310		564	672	775	655	451	220	5	4,559
154	Rectum	1	-	-	1	3	7	18	42	51	125	202	256	329	420	413	354	225	140	-	2,587
155	Biliary passages and liver				100						-	Sec.		-	-		12.22			in.	1000
158	(specified primary) Liver (secondary and unspecified)	5	-	2 -	-	2	-	2135	53	10	23	28	57	85	126	140	125	56	41	1	708
157	Pancreas		1	_		1	12	1	о 5	7 19	12 44	29 79	25 120	33 193	42 200	42	32	24	11	-	262
158	Peritoneum	1	1	1		1	~	0 5	0	3	44	14	17	23	200	271 21	184 14	141 3	71 3	1	1,335
159	Unspecified digestive organs	-	-	-	1	-	_	-		-	1	4	±1 _	1	4	1	14	0	0 -	1	13
160	Nose, nasal cavities, etc.	-	-	-	1	-	-	-	-	10	8	11	13	17	17	19	17	11	6	-	130
	Contraction of the second second second			and the second					-	· (615)		1005	and the second						Ű		
161	Larynx	- 1	-	-	-	1	3	2	3	5	9	10	16	12	9	15	12	6	2	1 - 1	105
162	Lung (specified primary),		1								- Sugar	-	100 - 10 - 10 - 10 - 10 - 10 - 10 - 10					- United	- State	in the state	
187	bronchus and trachea Lung (unspecified primary or	2		-	-	-	9	15	66	113	199	277	371	422	426	383	246	134	51	1	2,715
103	secondary)	1	-	-		2		-	64 X			1	1	1	2	2	1		-		8
164-165	Mediastinum and thoracic organs											-	-	-	~	~	-				0
	(secondary)	-	-	-	-	-	-	2	2	2	3	10	14	8	8	8	6	3	3	-	69
Contraction of the second second	Breast	-	-	-	2	8		242	000	1,032		1,582	1,606	1,606	1,487	1,352		638	353	20	13,197
171	Cervix uteri		-	-	1	3		104	300	445	485	495	431	466	350	276	182	91	41	5	3,702
172	Corpus uteri	-	-	-	-	1	.1	14	43	108	191	399	517	424	380	276	187	84	44	3	2,672
173	Other parts of uterus, including chorionepithelioma		1	The second	1							and the second		200	and the second	- 27			i and	-	
174	Uterus, (unspecified)	-	-	-	1	32	1	2 -	2	7	23	1	2 10	17	- 4	6	- 5	- 3	-		22 51
	Ovary, Fallopian tube and broad		24.5	E.	RE	2			81 4 T	1	0	0	TO	./	4	0	Ð	3	4	1	51
_10	ligament	_	1	3	7	21	22	36	96	166	311	370	421	407	347	270	168	96	45	6	2,793
176	Other and unspecified female				-	1										~	100	00	40		
	genital organs	1	-	1	-	-	2	6	13	13	32	41	40	84	116	133	101	79	53	1	716
	Post-manage and states	1	-12	SI		-	1	-	1 10		-	1	-	- Per	in main		a la			-	
	A DESCRIPTION OF THE OWNER OF THE		and a	- AN	1000	Sec. State	123		The sugar		the second	2 - Carlos	D- Watan	and and and	Ent and man				1. 1. 1. 1. 1.	No. of Street,	

.

180 181 190 191 192 193.0 193.0 223 193.1-9 194 195.0	Kidney Bladder and other urinary organs Melanoma of skin Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant	21 2 - 9 4 21 15 13 -	5 11112 2 59 3 1	1 	2 -95 - - 112 4 4	3 147711 1 101 7 5	2 47911 4 153 7 8	7 229 40 63 2 21 5 7 14	6 12 49 82 13 4 2 2 9 8 5 12	22 12 41 143 19 12 3 3 32 9 11 21	36 39 47 240 36 11 2 59 15 26 24	33 74 40 298 55 10 5 84 20 24 30	58 100 32 410 72 7 9 93 28 34 29	79 133 34 498 87 7 5 81 20 26 38	71 171 43 549 109 12 4 4 46 13 28 53	58 189 39 653 151 14 2 18 8 19 44	777 171 34 581 141 10 1 1 10 3 5 32	28 116 22 441 122 4 1 1 - 2 27	17 58 14 260 100 1 - 1 - 4 13	2 1 15 2 - - 1	528 1,085 465 4,230 918 109 50 581 165 226 356
195.1-8 224 195.1-8 224 196 197 198 199	neoplasm	7 - 2 184 -1	273 11	- - 15 6 -	- 1 15 8 - 1		2 566 1-	1 - 3 1 6 13 10	2 - - 8 7 16 16 16	1 - 2 5 7 14 32	5 - 1 8 12 13 6 3	1 - 7 5 9 20 10 84	4 - 3 7 14 20 13 117	1 - 1 5 17 26 22 187	3 - 3 19 17 17 16 207	3 - 2 13 21 13 197	2 - - 16 19 9 157	- 1 11 22 6 89	- 1 - 4 13 8 41		30 1 28 51 194 249 116 1,208
200.0 200.1 201 202 203 204.3 part 204.0	Reticulum - cell sarcoma Lymphosarcoma Hodgkin's Disease Other forms of Lymphoma (reticulosis) Multiple myeloma (plasmocytoma) Lymphatic leukaemia - acute Lymphatic leukaemia - chronic and unspecified	1 4 - 27 1	1 4 1 1 26 3	2 4 10 1 15 1	729 215 1	4 3 26 4 - 4 -	3 3 3 1 4 1 - r	8 5 22 6 1 3 1	5 11 21 7 4 1 3	11 5 19 6 7 2 3 16	17 12 14 7 22 9 7	25 30 22 14 28 13 11	27 32 26 16 37 13 13 17 25	40 42 30 22 66 8 26 34	41 43 24 14 63 12 43 27	32 42 33 11 60 17 32 30	24 33 25 9 41 12 36 22	14 13 8 14 21 4 17	694 142 73	141 111 1	268 298 345 143 355 173 208 280
2. 2.97	unspecified Leukaemia - cell type not stated - acute Leukaemia - other stated and unstated cell type	- 16 3	8 1 3 1 6 -	10 1 3 - 3 -	8 12 - 3 2 -	7 32 - 4 1 -	7 6 1 - 5 1	16 9 3 - - - 2	10 5 5 1 1 - 2	10 14 1 - 3 2 2	10 21 7 1 - - 3	10 21 8 2 6 1 2	20 4 3 6 1	35 6 3 3 2 2 4	19 5 4 6 1 7	33 6 1 2 7 5	22 14 3 2 7 5 6	77 3 2 2 3 1	6 - 2 - 4 4	ALL ALL ALLA STR	217 62 22 73 33 47
	Premalignant conditions - all sites Doubtful malignancy - all sites All sites	- - 184	_ _ 121	- - 132	- - 152	3 	8 - <b>358</b>	19 	33 - 1,684	34 1 <b>2,741</b>	20 1 <b>4,285</b>	21 1 5,283	5 5 6,157	5 - 6,964	3 1 7,215	2 _ 7,141	ද  5,704	3 1 <b>3,651</b>	 1,947	_ 74	158 11 54,784

## Appendix Table C. Registrations of newly diagnosed cases of cancer among males by site and age.

Urban areas of England and Wales, 1961

	stead interest state - 877										Age	-group	)				1			Age	
	ICD No. and site description	0	5-	10-	15-	20-	25-	30-	35	40-	45**	50-	55-	60-	65-	70-	75-	80-	85 & over	not stated	Al l ages
140	Lip same - torat actres and	1		-	-	~	2	1	12	10	17	33	35	30	35	52	37	30	21	-	315
141	Tongue	1	- 1	1	-	1	1	3	6	8	8	21	20	34	38	43	51	30	20	-	285
142	Salivary gland	-	-	2	3	4	12	9	16	10	13	22	11	18	19	12	8	6	3	-	168
143	Floor of mouth	-	-	*	-	1	-	-	1	1	5	Б	9	19	11	15	15	10	6	-	98
144	Other mouth (specified and unspecified)			*				2	1	5	9	9	15	30	35	37	36	23	12	-	214
145	Oral mesopharynx	-	1	*	-	-		1	1	2	3	10	26	30	22	23	19	14	7	-	159
146	Nasopharvnx	1	3	3	3	1	2	1	5	7	6	9	10	11	7	8	4	3		-	84
147	Hypopharynx	-	-	+	-	1	1	-	1	• 1	4	12	22	43	34	31	35	11	7	1	204
148	Pharynx (unspecified)	-	-	1		-	1	1	-	2	1	Б	13	8	14	12	12	11	1	-	81
150	Oesophagus	-		1	-	-	1	4	3	11	32	59	89	137	137	133	120	80	33	1	841
151	Stomach	1	-	-	-	2	7	19	54	90	231	418	651	748	749	731	509	238	88	2	4.534
152	Small intestine, including duodenum		-	+	1	-	-	1	3	4	14	14	16	19	12	9	4		-	2 2	100
153	Large intestine, except rectum	-	-	~	2	7	5	25	47	50	128	199	297	384	426	457	381	233	105	1	2,747
154	Rectum	-	-	1	-	4	4	11	21	54	98	200	323	409	415	416	344	214	92	2	2,608
155	Biliary passages and liver	3	XE		L		21	-	~	17		1		~ 1	0.5	20	70		17		
156	(specified primary) Liver (secondary and unspecified)	4	-	1	+	5	1 2	5	7	14	22 8	41 28	59 45	71 47	85 53	68 47	38 11	28 11	13 5	1 1	457 268
157	Pancreas	-	-	-	-	1	2	1	13	32	59	115	174	192	228	182	155	84	32	3	1.269
158	Peritoneum	-	-	1	1	1	2	5	3	7	7	6	15	12	11	Б	2	5	1		84
159	Unspecified digestive organs		-	-	-	-	-	-	1	-	-	-	-	-	3		1	-	1	-	5
160	Nose, nasal cavities, etc.	-	-	-	-	-	-	-	3	6	9	13	16	31	21	21	19	11	4	-	154
161	Larynx	-	~	2	-	1	2	2	7	24	46	68	115	126	122	94	62	31	14	2	716
162	Lung (specified primary), bronchus				7.8														_		1 1200
	and trachea	1	-	-	2	8	11	45	134	274	688	1,656	2,548	2,904	2,449	1,765	910	300	84	12	13,791
163	Lung (unspecified primary or secondary)	4	-	r	-	-		-	1	-	-	2	2	1	2	-	3	-	-	*	11
164-165	Mediastinum and thoracic organs (secondary)	.2	1	1			2	1	1	1	4	5	21	17	17	10	10	1	2		99
170	Breast	2		*	-	2	~	1	3	3	9	6	21	14	16	20	12	8	2 .		115
177	Prostate	1	-	-	-	-	-	-	-	4	16	52	158	284	492	700	732	478	229	2	3,148
178	Testis - seminoma	1	2	-	2	8	28	31	34	25	19	14	11	8	3	2	3	1	-	1	191
178	Testis - other types of growth	2	1	-	8	24	25	25	14	10	8	4	Б	3	1	4	1	3	-	-	138
179.0	Penis	-	-	-	-	*	1	3	3	7	11	19	17	28	33	22 8	25	21	11	-	201
179.1	Scrotum	-	-	-	-	-	-	-	-	2	5	4	15	10	8	6	5	3	3	*	61
179.7-9	Other and unspecified male genital organs	5	1	1	-	-	The		-	1	1	1	1	2	12	-	1 70	-	-	-	6
	our section and exchlame of skin		a t	-	29		CR.	10	1	10			1 ato	2	A REAL	1 124	1 200	E 1986	1 700	1	\$ 2.579
180	Kidney	17	- 4	-		Б	4	3	14	27	51	98	105	127	97	71	62	35	Б	2	727
181	Bladder and other urinary organs	2	-	1	-	4	10	8	30	46	99	179	281	391	432	420	316	196	75	6	2,494
190	Melanoma of skin	1	1	2	-	2	6	9	14	13	18	18	18	18	11	12	12	10	7.	-	172
191	Rodent ulcer	-	-	~	3	21	12	31	105	175	295	398	475	535	442	452	345	257	153	23	3,703

191 192	Other malignant neoplasm of skin Eye	-	2	-	-	3	- 2	5	14	37 6	49 11	86 9	109 15	130 10	160 9	162 9	162 5	134 3	87	5 1	1,143
193.0	Brain - malignant neoplasm, other than glioma	2	2 2	-	3	-	5	1	4	5	4	Б	6	6	1	2	1	-	-	4	47
193.0	Brain - gliomas (not specified as benign)	21	13	22	7	12	14	16	35	44	68	92	110	92	41	17	4	2	-	1	611 140
223 193 <b>. 1</b> 9	Brain - benign neoplasm Other parts of nervous system -	2	2	4	5	7	6	5	12	6	7 10	10 23	23 18	21 14	22	7	1	1	1	-	140
	any type of neoplasm	7	2	4	6	4	5	11	9	11	4	11	10	14	12	15	9	5	1		90
194 195.0	Thyroid gland Suprarenal gland - malignant neoplasm	6	1	1 2	1	-	1	1	-	*	1	2	1	2	2	5	1	1	-	-	27
224 195 <b>.1-</b> 8	Suprarenal gland - benign neoplasm Other endocrine glands - malignant	1	-	2 1	-	-	-	-	-	-	~	-	1	1	-	-	-	-	-	-	3
224	neoplasm Other endocrine glands - benign	-	-	2	1	3	1	Б	-	1	1	4	2	Б	-	-	-	-	-	+	25
196	neoplasm Bone	1	4	7	25	1 11	*	4	6 5	777	7 13	5 15	8 23	4 26	3 21	1 19	17	5	- 4	-	51 223
197 198	Connective tissue Lymph nodes (secondary and	6	-	3	9	9	8	9	10	11	15	23	18	29	19	17	15	10	1		212
199	unspecified) Other and unspecified sites	1		2	1	1 2	25	1 4	2 9	1 21	10 33	18 66	23 106	25 122	22 135	22 105	16 82	8 38	16	-	748
200.0	Reticulum - cell sarcoma Lymphosarcoma	- 10	27	67	13 8	53	12	10	15 10	11 14	19 22	20 29	35 42	29 46	19 37	25 28	8 21	1 11	3	-	233 310
201	Hodgkin's Disease Other forms of lymphoma	1	7	16	16	34	49	32	32	34	44	40	38	35	30	19	10	4	3	-	444
203	(reticulosis) Multiple myeloma (plasmocytoma)	1	1	1	2 +	5	1	72	6 5	6 13	8 19	10 18	18 39	14 51	14 31	9 32	3 15	3 10	5 5	1	114 241 139
204.3 part 204.0	Lymphatic leukaemia - acute Lymphatic leukaemia - chronic	38	5	7	10	Б	Б	7	5 3	5 10	5 10	5 14	7 30	7 33	13 41	8 47	5 43	2 22	6	1 1	263
204.3 part	and unspecified Myeloid leukaemia - acute	2 14	8	11	8	9	6	2 12	20	14	16	17	18	17	32	19	10	13	4	1	249
204.1	Myeloid leukaemia - chronic and unspecified	4	1	2	2	7	5	8	5	13	12	16	21	17	14	22	16	12	1	-	178
204.2 part 204.2 part	Monocytic leukaemia - acute Monocytic leukaemia - chronic and	4	-	-	3	3	1	-	2	2	4	1	3	8	- And	7	5	-	1	+	48
- 1.435	unspecified Leukaemia - cell type not stated -	1	-	-	-	-	-	-		2	**		3	3		4	- 3	100	2		14
204.4	acute Leukaemia - other stated and	14	9	4	3	1	2	3	1	3	4	3 2	3	6 5	5	5	0 1	- 2	~	200	23
200.2 & 205	unstated cell type Other lymphoid tissue and mycosis fungoides			-	-	1 3	3	1	1	5	4	~ 7	4	6	9	4	2	2	1		53
	Premalignant conditions - all sites		-		-		-	-		-	1	5	4	3	Б	2	1	1	-	*	22
	Doubtful malignancy - all sites	2	-	-	-	-	-	-	**	1	-	-	2	2		-	1	1	1 170	67	9 46, 385
	All sites	192	86	115	150	209	288	421	779	1,223	2,348	4,296	0,385	7,519	7,191	0,490	4,700	2,001	1,179	07	

40

## Appendix Table D. Registrations of newly diagnosed cases of cancer among females by site and age

## Urban areas of England and Wales, 1961

					4			1			Age-	group			1		1		Les and	Age	A11
	ICD No. and site description	0	5-	10-	15-	20-	25-	30-	35-	40~	45-	50-	55~	60-	65-	70-	75-	80-	85 & over	not stated	2008
140	Lip	-	-	-	-		-	-	1	-	4	4	3	2	8	6	8	7	4	-	47
141	Tongue	-	-	-	-	-	1	-	-	3	4	10	37	15	19	27	24	15	9	-	134
142	Salivary gland	-	-	4	5	Б	11	15		11	18	20		18	10	18	10	14		-	212
143	Floor of mouth	-	-	-	-	-	-	-	1	-	-	7	3	3	2	7	9	5		-	39
144	Other mouth (specified and			1 P	15.2																
	unspecified)	-	*	-	1	1	1	1	3	4	2	11	12	16	25	29	18	11	6	-	141
145	Oral mesopharynx	-	**	-	-	-	-	-	1	3	-	7	9	10	7	6	6	7	8	-	64
146	Nasopharynx		***	-	2	**	-	-	-	~	2	3	Б	11	4	-	4	3	-	-	34
147	Hypopharynx	-	-	-	*	*	*	4	3	8 2	15	19	22	32	28	16	22	11	1	1	182
148	Pharynx (unspecified)	-	-	-	-	-	-	1	1	2	6	4	9	7	6	10	5	6	2	*	59
150	Oesophagus	-	-	-	-	-	-	6	7	16	22	58	46	75	105	100	116	80	32	1	664
151	Stomach	-	-	0 <b>-</b>	-	2	8	11	35	48	86	180	272	383	521	589	496	343	149	2	3,125
152	Small intestine, including			art.	100	AND T									CAL	000	100	040	1.10	~	71-20
	duodenum	-	1	-	-	-	-	1	Б	4	4	Б	12	15	12	8	7	6	1 1	-	81
153	Large intestine, except rectum	-	-	4	8	12	16	24	57	93	171	254	347	454	540	639	543	356	181	4	3,703
154	Rectum	. +	-	-	1	2	7	15	33	41	106	159	211	278	354	317	295			-	2,122
155	Biliary passages and liver			21		9			0 20	1				and particular	a alta			1			al and
	(specified primary)	4	-	-	*	1	-	1	4	10	19	26	45	74	96	114	99	45		1	577
156	Liver (secondary and unspecified)	-	-	-	-	-	1	1	2	7	9	23	17	28	36	30	23	23	10	-	210
157	Pancreas	-	1	-	*	1	1	3		18	39	59	96	157	163	228	147	124	58	1	1,099
158	Peritoneum	1	1	1	-	1	-	1	-	2	7	12	13	20	21	19	11	3	a second second second second	1	116
159	Unspecified digestive organs	-	*	-		*	-	-	-	18 2 - 8	1	4	*	1	3	1	2	-	-	-	12
160	Nose, nasal cavities, etc.	F	-		1	-	-	*	-	8	8	9	12	14	15	14	14	11	4	-	110
161	Larynx	-	-	-	-	1	3	2	3	4	8	8	14	9	7	14	9	4	1	-	87
162	Lung (specified primary),																			4	
	bronchus and trachea	2	-	-	-	-	7	14	52	90	165	223	315	361	355	324	209	120	47	1	2,285
163								1	1.4.5												
	secondary)	-	-	-	-	*	-	-	-	-	-	-	1	-	2	2	1	-	-	-	6
164-165	Mediastinum and thoracic			The second					127 1					100			1				1
	organs (secondary)	-	-	-	-	-	-	2	1	2	3	10	11	7	6	7	6	3	1	-	59
170		-	-	-	2	8	55	195	475			1,322	1,337	1,337	1,220	1,115	843	523	297	17	10,868
171	Cervix uteri	-	-	-	1	2	25	72	247	360	409	408	356	385	301	237	150	80	35	4	3,072
172	Corpus uteri	**	-	-	-	1	1	9	38	90	156	337	407	343	299	224	156	66	40	3	2,170
173																E a state					100 m
	chorionepithelioma	-	-	-	1	2	1	1	2	6	2	1	2	1	-	-		-	-	-	19
174	Uterus, (unspecified)	*	+	-	-	2	-		-	-	3	6	8	Б	2	3	4	1	4	-	38
175				1		1	al	-		1		-	E LAPAR	E gran			an	P. Same	1 inte		
Contraction of the second	broad ligament	-	*	3	7	17	21	32	77	141	249	319	351	323	285	226	138	79	41	5	2,314
176	Other and unspecified female	2		1	- all	- 3	-		1.1.1.1		-		1 June	1	1		- Jones			1	1000
	genital organs	1	-	1	-	-	2	6	10	10	25	32	33	64	101	101	78	62	41	1	568
	- The section of the sector of the sector of the sector			Call S	1 miles	- Lama	1	19	and the second		1			A REAL	Anna Maria	100	495	1			a chai

180 181 190 191 191 192	Eye	17 1 7	211112		1 1 0 10 1 V	8 4 8 4 4	2428 22811	Б122562	5 7 42 62 12 3	18 11 31 121 13 10	32 35 43 199 29 11	27 63 29 242 44 8	50 90 26 343 58 7	69 110 30 420 74 5	58 148 33 459 90 10	52 167 27 539 116 13	67 144 30 466 115 8	27 98 17 342 90 4	11 47 11 211 83 1	21121	447 927 377 3,466 735 94
	Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified	4	2	3	-	1	3	1	2	З	2	4	7	4	З	2	1	1	-	-	43
223	as benign)	19 10	21 8	23 2	10 2	9 1	92	18 4	19 6	25 4	45 15	59 15	79 20	65 16	39 10	14 8	9 3	- 1	1		464 127
193.1-9	Other parts of nervous system - any type of neoplasm	7	2	3	4	6	3	6	4	9	22	19	30	20	23	15	Б	-	4	-	182
194		-	-	1	2	4	Б	14	11	12	18	23	24	32	46	34	27	19	11	-	283
195.0	neoplasm	Б	-	-	-	+	-	1	2	1	4	1	4	1	3	3	1	-	-	-	26
224 195 <b>.1-</b> 8	neoplasm	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	1
	malignant neoplasm Other endocrine glands - benign	1	+	-	-	-	1	3	-	1	1	6	3	1	3	2	-	-	-	-	22
196 197	neoplasm Bone Connective tissue	153	273	1 12 6	10 6	75	4 4 4	1 6 10	8 7 13	4 6 10	8 11 11	3 6 15	9	4 12 23	1 17 13	2 10 17	15 16	8 19	48	111	45 156 198
198 199	Lymph nodes (secondary and unspecified) Other and unspecified sites	-1	1		1	13	1	1 9	1 14	2 30	4 50	6 67	10 86	20 159	15 168	16 169	7 126	6 77	5 33	-	96 994
200.0 200.1 201	Lymphosarcoma	1 21	131	238	7 2 24	4 3 23	2 2 2 25	8 3 19	4 9 18	9 4 14	15 12 12	15 26 18	22 27 24	37 38 24	32 38 20	28 33 27	21 29 20	13 10 7	8 6 4	1	226 252 288
203 204.3 part	(reticulosis) Multiple myeloma (plasmocytoma) Lymphatic leukaemia - acute	4 - 24	1 18	1 12	1 - 4	4	31	6 1 3	6 4 1	4 7 1	5 17 8	12 24 7	15 31 10	19 57 5	12 <b>49</b> 10	10 44 16	6 33 10	9 12 3	1 4 2	1.1.1	119 284 137
204.0	Lymphatic leukaemia - chronic and unspecified	1	2	-	-	-		-	3	3	6	8	10	21	36	28	28	16	6		174
	Myeloid leukaemia - acute Myeloid leukaemia - chronic and	8	8	8	6	5	6	11	15	9	7	15	21	25	26	28	16	9	3	-	224
204.2 part	unspecified Monocytic leukaemia - acute	1	1 3	1 3	1	2 1	6 1	73	4 4	10	15 6	18 7	16 4	32 5	17 5	25 4	13 2	42	6	+ +	179 51
	Monocytic leukaemia - chronic and unspecified	-	1	1	1		-	-	1	-	1	1	3	3	З	1	2	2	2	-	20
204.3 part	Leukaemia - cell type not stated - acute Leukaemia - other stated and	14	6	1	1	З	4	-	1	2	-	5	6	2	6	2	7	1		•	61
	unstated, cell type Other lymphoid tissue and	3		-	1	1	1	-	-	2		1	-	2	. 1	5	Б	and and the	3	-	27
	mycosis fungoides	*	-	-	ł		-	2	2	2	3	1	8	3	6	Б	4	1	3	nette	40
	Premalignant conditions - all sites Doubtful malignancy - all sites	1 1	1 1	+ +	11	3	7	18	23	28 1	18 1	18 1	34	4	3	-	2	2	-1		127 9
	All sites	147	101	106	126	159	293	643	1,395	2,207	3,512	4,352	5,079	5,788	5,955	5,891	4,691	2,996	1,618	59	45,118

42

## Registrations of newly diagnosed cases of cancer among males by site and age Appendix Table E.

Rural areas of England and Wales, 1961

	strong items and all and a star		1								1 201	e-grou		П	Г			1	85 &	Age not	Al
	ICD No. and site description	0-	5-	10-	- 15-	20-	- 25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	over	stated	4
140 141	Lip Tongue	-	-	-	-	-	-	1	4	5	10	12	26	30 7	22 5	32 8	29	14	7	1	
142	Salivary gland	- 1.5	-	-	1	1	5	-	-3	2 4	1 5	6 -	4	1	5	8	8 1	92			
	Floor of mouth Other mouth (specified and	-	-	-	-	-	-	-	+	-	-	-	1	2	6	-	6			-	
	unspecified)	- \	-	-	-	-	-	-	-	-	1	3	5	5	11	8	9		2	-	
145 146	Oral mesopharynx Nasopharynx	1	-	- 1	- 1	-	-	-	1	2	- 2	24	5 5 2 7	5 2 3 3	11 12 2	8 3 1	8		3	-	
147	Hypopharynx	-	-	-	-	-	-	1	-	-	-	4	2 7	3	~ 4	4	1 4	3	1 2	-	
148 150	Pharynx (unspecified) Oesophagus	-	-	-	-	=	-	-	-1	1 2	1 13	- 14	- 25	4 31	- 24	- 47	2 32	1	2	-	
in the second				-		T				100		14			N. C. S.	- AND	20	1			
151 152	Stomach Small intestine, including		-	-	-	-	-	3	6	26	41	87	113	180	160	169	122	72	2,3	1	1,
4.5.7	duodenum	-	-	-	-	-	-	-	1	2	2	3	3	4	3	Б	1		-	2	
153 154	Large intestine, except rectum Rectum		-	-	-	1	5	36	6 6	15 11	29 23	41 44	60 79	96 92	110 111	100 101	83 99		22 19	2	
155	Biliary passages and liver	in the										1			A.S.			1000	1. 2.3	1 -	
450	(specified primary)	2	-	-	-	-	2	2	1	1	2	7	14	20	22	9	11	7	4	-	1
															S S S S S M						
															8.28.25.21 M	REP REAL	R # 13 # 25 and an	TRATES	Harris Harris	to me to other 21 is	and the second s
「「「「「「」」」	ALCONSTANT AND ALCONSTANT ALCONST	101, Ton	and Rever Cards 65 1. 45	3 2 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	21 21 EN 2 2 2 2	AD ALL ADDRESS OF A STATE OF A	10. 40 13 13 14 11 10	The state of the fight of	as shed wild up at	「 二 二 二 二 二 二 二 二 二 二 二 二 二 二 二 二 二 二 二	\$1853 600 51 au	C. S.S. We aman	THE AD	248 Br. mi.e	RARGES N	<b>新教命 张马</b> 龙, 24	238 12 a.	1. 25 1. 25 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20 1. 20	11 4 11 11 11 11 11 11 11 11 11 11 11 11	the standard standard	
191	Rodent ulcer		1	1 2 2 4 444-12. 12		2			18	40	59	87	105	135	142	125	102	69	42	6	
191	Rodent ulcer Other malignant neoplasm of skin	N11	1.1.1.		111	2		11	18 6 -	40   9	22	27	105 29 3	135 47 2	142   61   4	125 58 1	102 78 1	69 38 1	42 40 -	6 - -	4
191 192	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other	<u>811</u>	TTT	1 1 1		-	-	2 -	6 -	9	22 2	27 2	29 3	47 2	61 4	58 1	78 1	38 1	40 -	-	L
191 192 193.0	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 1 1 -		2	and a second of the		6	91	22	27	29	47	61	58	78 1 -	38	40	-	4
191 192 193.0 193.0	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign)		5	3	3	2	- - 3	2 - 1 7	6 - - 6	9 1 - 11	22 2 1 9	27 2 2 29	29 3 2 27	47 2 1 31	61 4 2 16	58 1 2 4	78 1 - 1	38 1 - 2	40 - -		1
191 192 193.0 193.0 223	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm	1						2 - 1	6	9 1 -	22 2 1	27 2 2	29 3 2	47 2 1	61 4 2	58 1 2	78 1 -	38 1 -	40 - -		1
191 192 193.0 193.0 223	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign)	1	5	3	3	2	- - 3	2 - 1 7	6 - - 6	9 1 - 11	22 2 1 9	27 2 2 29	29 3 2 27	47 2 1 31	61 4 2 16	58 1 2 4	78 1 - 1	38 1 - 2	40 - -		ید 1
191 192 193.0 193.0 223 93.1-9	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm	1	53	3 1	3 1	- - 2 1	B2	2 - 1 7 3	6 6 3	9 1 - 11 1	22 2 1 9 3	27 2 2 2 29 5	29 3 2 27 6	47 2 1 31 4	61 4 2 16 3	58 1 2 4 2	78 1 - 1 -	38 1 - 2 1	40 _ _ _	11 1 11	ید 1
191 192 193.0 193.0 223 93.1-9	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant	1 6 - -	5 3 1 -	3 1 3 -	3 1 2 -	- - 2 1 2 -	1 1 10 22 1 1	2 - 1 7 3 2	6 - - 6 3 1 -	9 1 - 11 1 3 1	22 2 1 9 3 5 2	27 2 2 29 5 6 -	29 3 2 27 6 4 1	47 2 1 31 4 2 4	61 4 2 16 3 2 2	58 1 2 4 2 4	78 1 - 1 - 5	38 1 - 2 1 - 1	40 - - - -	1.1 1.1 1.	ید 1
191 192 193.0 193.0 223 93.1-9 194 195.0	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant neoplasm	1	5 3 1	3 1 3	3 1 2			2 - 1 7 3 2	6 - - 6 3 1	9 1 - 11 1 3	22 2 1 9 3 5	27 2 2 29 5 6	29 3 2 27 6 4	47 2 1 31 4 2	61 4 2 16 3 2	58 1 2 4 2 4	78 1 1 1 1	38 1 - 2 1 -	40 - - -	11 1 1 1	
191 192 193.0 193.0 223 93.1-9 194 195.0 224	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant neoplasm Suprarenal gland - benign neoplasm	1 6 - -	5 3 1 -	3 1 3 -	3 1 2 -	- - 2 1 2 -	1 1 10 22 1 1	2 - 1 7 3 2	6 - - 6 3 1 -	9 1 - 11 1 3 1	22 2 1 9 3 5 2	27 2 2 29 5 6 -	29 3 2 27 6 4 1	47 2 1 31 4 2 4	61 4 2 16 3 2 2	58 1 2 4 2 4	78 1 - 1 - 5	38 1 - 2 1 - 1	40 - - - -	11 1 1 1	1
191 192 193.0 193.0 223 93.1-9 194 195.0 224	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant neoplasm Suprarenal gland - benign neoplasm Other endocrine glands - malignant	1 6 - -	5 3 1 - 1	3 1 3 -	3 1 2 - -	21 2	1 1 10 22 1 1 1	2 - 1 73 2 2	6 6 3 1	9 1 - 11 1 3 1 -	22 2 1 9 3 5 2 2	27 2 2 29 5 6 -	29 3 2 27 6 4 1	47 2 1 31 4 2 4 1	61 4 2 16 3 2 2 2 1	58 1 2 4 2 4	78 1 - 1 - Б -	38 1 - 2 1 - 1 1	40		1
191 192 193.0 193.0 223 93.1-9 194 195.0 224 .95.1-8	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant neoplasm Suprarenal gland - benign neoplasm Other endocrine glands - malignant neoplasm Other endocrine glands - benign	1 6 - - 1 -	5 3 1 - 1 -	3 1 3 - - -	31 2		1 1 1 1 1 1 1	2 - 1 73 2 2 - 1	6 - 6 3 1 - - 1	9 1 - 11 3 1 - - 1	22 2 1 9 3 5 2 1 - 2	27 2 29 Б 6 – –	29 3 2 27 6 4 1 - -	47 2 1 31 4 2 4 1 -	61 4 2 16 3 2 2 1 - 3	58 1 2 4 2 4	78 1 - 1 - 5 -	38 1 - 2 1 - 1 1 -	40		1
191 192 193.0 193.0 223 93.1-9 194 195.0 224 .95.1-8 224	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant neoplasm Suprarenal gland - benign neoplasm Other endocrine glands - malignant neoplasm Other endocrine glands - benign neoplasm	1 6 1 1 2	53 1 - 1 -	313-	31 2			2 - 1 7 3 2 2 - - 1	6 - 6 3 1 - - 1 1	9 1 - 11 1 3 1 - 1 2	22 2 1 9 3 5 2 - 2 3	27 2 29 5 6 -	29 3 2 27 6 4 1	47 2 1 31 4 2 4 1 - - 1	61 4 2 16 3 2 2 1 -	58 1 2 4 2 4	78 1 1 1 - 5 - -	38 1 - 2 1 - 1 1 -	40		1
191 192 193.0 193.0 223 93.1-9 194 195.0 224 .95.1-8 224 .95.1-8 224 196 197	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant neoplasm Suprarenal gland - benign neoplasm Other endocrine glands - malignant neoplasm Other endocrine glands - benign neoplasm Bone Connective tissue	1 6 - - 1 -	5 3 1 - 1 -	3 1 3 - - -	31 2	- - 2 1 2 1 2 - - - 1 1	1 1 1 1 1 1 1	2 - 1 73 2 2 - 1	6 - 6 3 1 - - 1	9 1 - 11 3 1 - - 1	22 2 1 9 3 5 2 1 - 2	27 2 29 5 6 	29 3 2 27 6 4 1 - - 1	47 2 1 31 4 2 4 1 -	61 4 2 16 3 2 2 2 1 - 3 -	58 1 2 4 2 4 3 - - -	78 1 - 1 - 5 -	38 1 - 2 1 - 1 1 -	40		ید 1
191 192 193.0 193.0 223 93.1-9 194 195.0 224 .95.1-8 224 .95.1-8 224 196 197	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant neoplasm Suprarenal gland - benign neoplasm Other endocrine glands - malignant neoplasm Other endocrine glands - benign neoplasm Bone Connective tissue Lymph nodes (secondary and	1 6 1 - 2 3	5 3 1 - 1 - - 1 -	3 1 3 1 1 1 1 1 4 1	312	- - 2 1 2 1 2 - - - 1 1 1 -	- - - - - - - - - - - - 1	2 1 73 2 2 - 1 1 121	6 - - 6 3 1 - - 1 1 2	9 1 - 11 1 3 1 - 1 2 2 2	22 2 1 9 3 5 2 2 3 2	27 2 2 29 5 6 5	29 3 2 27 6 4 1 - - 1	47 2 1 31 4 2 4 1 - - 1 4	61 4 2 16 3 2 2 2 1 - 3 - 3	58 1 2 4 2 4 3 - - - 4	78 1 1 1 1 5 1 1 1 2	38 1 - 2 1 - 1 1 - 1 -	40		
191 192 193.0 193.0 223 93.1-9 194 195.0 224 .95.1-8 224 196 197 198	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant neoplasm Suprarenal gland - benign neoplasm Other endocrine glands - malignant neoplasm Other endocrine glands - benign neoplasm Bone Connective tissue Lymph nodes (secondary and unspecified)	1 6 - - 1 - 2 3 -	53 1 - 1 - 1	3 1 3 - - - 4	31 2	- - 2 1 2 - - 1 1 - 2		2 - 1 73 2 2 - 1 12	6 - - 6 3 1 - - 1 2 3	9 1 - 11 1 3 1 - 1 2 2	22 22 1 9 3 5 2 2 3 2 2	27 22 29 5 6 1 1 1 5 3	29 3 2 27 6 4 1 - - 1 4 4	47 2 1 31 4 2 4 1 - 1 4 8	61 4 2 16 3 2 2 1 - 3 6	58 1 2 4 2 4 3 	78 1 - 1 - 5 - - - 2 1	38 1 - 2 1 - 1 1 - 1 1	40 		
191 192 193.0 193.0 223 .93.1-9 194 195.0 224 195.1-8 224 196 197 198 199	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant neoplasm Other endocrine glands - malignant neoplasm Other endocrine glands - benign neoplasm Other endocrine glands - benign neoplasm Bone Connective tissue Lymph nodes (secondary and unspecified) Other and unspecified sites	1 6 - - 1 - 2 3 - 1	5 3 1 - 1 - 1 - 1 - - - - - - -	3 1 3 	31 2	- - 2 1 2 - - 1 1 - 2 - 1 - - 1	- - - - - - - - - - - 1 1	2 1 7 3 2 2 1 1 1 1 2 1 2	6 - - 6 3 1 - - 1 2 3 - 5	9 1 - 11 1 3 1 - 1 2 2 2 6	22 2 1 9 3 5 2 1 - 2 3 2 2 3 8	27 2 29 5 6 - - - - - 5 3 6 12	29 3 2 27 6 4 1 - - 1 4 4 8	47 2 1 31 4 2 4 1 - 1 4 8 3	61 4 2 16 3 2 2 1 - 3 6 6	58 1 2 4 2 4 3  - 4 4 5	78 1 - 1 - 5 - - 2 1 5 19 5	38 1 - 2 1 - 1 1 - 1 1 1	40 		ید 1
191 192 193.0 193.0 223 93.1-9 194 195.0 224 95.1-8 224 196 197 198 199 200.0 200.1	Rodent ulcer Other malignant neoplasm of skin Eye Brain - malignant neoplasm, other than glioma Brain - gliomas (not specified as benign) Brain - benign neoplasm Other parts of nervous system - any type of neoplasm Thyroid gland Suprarenal gland - malignant neoplasm Other endocrine glands - malignant neoplasm Other endocrine glands - benign neoplasm Bone Connective tissue Lymph nodes (secondary and unspecified) Other and unspecified sites Reticulum cell sarcoma Lymphosarcoma	1 6 1 - 23	5 3 1 - 1 1 - 1 - 1 - 1 - 1 -	3 1 3 1 1 1 1 1 4 1	31 2	- - - 21 2 - - - 1 1- 2 - - - 1 - - 2 -	- - - - - - - - - - 1	2 1 7 3 2 2 1 1 1 1 2 1 1	6 - - 6 3 1 - - 1 2 3 -	9 1 - 11 1 3 1 - 1 2 2 2 2	22 22 1 9 15 22 1 9 15 22 1 8 15 22 1 8 15 22 1 1 22 15 22 15 23 15 23 23 23 25 25 25 25 25 25 25 25 25 25 25 25 25	27 22 29 5 6 1 1 1 5 3 6	29 3 2 27 6 4 1 - - 1 4 4 4 8 28	47 2 1 31 4 2 4 1 - - 1 4 8 3 28	61 4 2 16 3 2 2 1 - 3 6 6 34	58 1 2 4 2 4 3 - - - - 4 4 5 29	78 1 - 1 - 5 - - - 2 1 9	38 1 - 2 1 - 1 1 - 1 1 1 1 4	40 		

	All sites	41	21	35	35	39	66	125	167	289	489	831	1,268	1,615	1,622	1,526	1,207	712	342	14	10,444
	Premalignant conditions - all sites Doubtful malignancy - all sites	-		150		115	-	-	-	1	1	-	-	-	ī	2	6-10	-	ACT .	-	5
	Descriptions and tions all sites			1			-	_	_	_	_	-	1	1	1	2	3	-	-	-	8
200.2 & 205	Other lymphoid tissue and mycosis fungoides	-	1	-	-	-	-	1	1	1	-	1	1	1	1	-	-	-	1	-	8
	unstated cell type	-	-	-		and the second	-	and the second second	-	-	-				1	-	1	-	-	-,	2
204.4	acute Leukaemia - other stated and	~	-		and the second		- +		for succession		-		and the second		and the second second					a vita	Y81
204.3 part		2		1		_	1			_	1	1	11-11-11-11-11-11-11-11-11-11-11-11-11-	- 1 1	2	「	3	1 2		12/2/2	10
204.2 part	Monocytic leukaemia - chronic and unspecified	-	-	-	-	-	-	-	l.	-		-	-		-	1	100 - 10 - 10	1	1		3
204.2 part		-	Ŧ	-	-	1	2	-	3	1	See.	1	2	2	1	4	2	-			
	unspecified	-	-	-	-	-	1	-	1	-	4	6	7	3	5	2	4	2	1	-	36 19
204.3 part 204.1	Myeloid leukaemia - acute Myeloid leukaemia - chronic and	2	1	7	2	-	2	5	3	4	Z	6	4	0	0	Ð	<b>–</b>	0			
	the man and the states		Ī						-		2	0		8	6	5	4	5		_	63
204.0	Lymphatic leukaemia - chronic and unspecified	-	1	_	-	1	-	-	1	1		2	10	12	15	8	18	5	1		75
204.3 part		10	4	4	3	-	-	-	-	-	1	3	1	2	4	1	2	3	-	-	20
203	Multiple myeloma (plasmocytoma)	-	-	-	-	-	-	2	1	5	7	Б	7	8	3	14	Б	1		-1	58
202	Other forms of lymphoma (reticulosis)	-		1	1	2	2	3	-	3	5	2	6	5	3	2	2	1	-	-	38 58 38
201	Hodgkin's Disease	-	-	6	4	6	11	12	6	5	9	11	14	11	1Z	.7	0	D			
200.1	Lymphosarcoma	1	2	1	4	2	3	1	5	25	5	9	8 14	11 11	8 12	3 7	73	35	1	-	123
200.0	Reticulum cell sarcoma	-	1	3	1	1	2	2	2	2	3	5	0	8	0	4	D	0			76

## Appendix Table F.

## Registrations of newly diagnosed cases of cancer among females by site and age

Rural areas of England and Wales, 1961

9.

											Ag	e-grou	p							Age	A11
	ICD No. and site description	0-	5-	10-	15-	20-	25-	30- 3	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85 & over	not stated	ages
140		-	-	-	_	-	-	-	-	- 15	-	-	2	1	2 1	2	1	1	2	-	11
141	Tongue	-	1 1 1	-	-	-	-	-	1	1	2	1	1	5	1	4	9	4	3	-	32
142	Salivary gland	-	-	1	1		3	7	4	1	8	6	4	8	3	6	2	-	3	1	58
143	Floor of mouth	-	-	-	-	-	-	-	-	-	-	2	2	2	3	2	2	2	-	-	15
144	Other mouth (specified and								34.4									1			1
	unspecified)	-	-	-	-	-	-	2	1	1	2	3	2	3	2	5	2	2	2		27
145	Oral mesopharynx	-	-	-	-	-	-	-	-	1	-	-	1	4	-	3	-	1	-	-	10
146	Nasopharynx	-	-	-	-	-	-	-	-	-	2	-	1993 H -	1	-	27	-				5
147	Hypopharynx	-	-	-	-	-	-	-	-	3	1	3	4	6	10	7	3	3	1	-	41
148	Pharynx (unspecified)	-	-	-	-	-	-	-	-	-	-	1	1	1	1	1	1	-	-	- 1	6
150	Oesophagus	-	-	-		-	-	1	2	2	2	10	16	11	22	24	15	17	9	1	132
151	Stomach	-	-	-	1	0	5	3	3	12	22	25	51	59	113	102	110	49	30	1	585
152	Small intestine, including	18 1			A. 16		Carlos a	-			19		100 P	at the				6-6	aller for		1 . 63
	duodenum	-	-	-	-	-	-	-	1	1	1	3	2	-	1	1	2	-	-	-	12
153	Large intestine, except rectum	-	-	-	1	-	-	9	10	19	50	56	86	110	132	136	112	95	39	1	856
154	Rectum	1	-	-	-	1	-	3	9	10	19	43	45	53	66	96	59	39	21	-	465
155	Biliary passages and liver															" and the		- the	L.		and the
	(specified primary)	1	-	2	-	1	-	1	1	-	4	2	12	11	30	26	26	11	3	-	131
156	Liver (secondary and unspecified)	-	-	-	-	-	-	-	1	-	3	6	8	5	6	12	9	1	1	-	52
157	Pancreas	-	-	-	-	-	1	-	2	1	5	20	24	36	. 37	43	37	17	13	-	236
158	Peritoneum	-	-	-	-	-	-	4	-	1	. 2	2	4	3	3	2	3	1 -	1		25
159	Unspecified digestive organs	-	-	-	-	-	-	-	-	-	-	- 1	- 1	- 3	1	- 5	-	1	6 -	-	1
160	Nose, nasal cavities, etc.	-	-	-	-	-	-	-	-	2	-	2	1	3	2	5	3		2	-	20
	stanting strange - pairtage											The second			-	-					
161	Larynx	-	-	-	-	-	-	-	-	1	1	2	2	3	2	1	3	2	1		18
162	Lung (specified primary), bronchus				1									1. A. A.						1	
	and trachea	-	-	-	-	-	2	1	14	23	34	54	56	61	71	59	37	14	4	-	430
163	Lung (unspecified primary or							1.0													
	secondary)	-	-	-	-	-	-	-	-	-	-	1	- 1	1	-	-	· · · ·		-	-	2
164-165	Mediastinum and thoracic organs				1				1												
	(secondary)	-	-	-	-	-	-	-	1	-	- 4	- 1	3	_ 1	2	1	-	-	2	-	10
170	Breast	-	-	-	-	-	12	47	85	213	307	260	269	269	267	237	189		56	3	2,329
171	Cervix uteri	-	-	-	-	1	2	32	53	85	76	87	75	81	49	39	32	11	6	1	630
172	Corpus uteri	-	-	-	-	-	-	5	5	18	35	62	110	81	81	52	31	18	4	-	502
173	Other parts of uterus, including	1 2 3 4			1 de													1.			- mark
	chorionepithelioma	-	-	1	-	1	-	1	-	1	- 1	- 1	-	-	-	-	-	-	-		3
174	Uterus, (unspecified)	-	-	-	-	-	-	-	-	1	-	-	2	2	2	3	1	2	-	- /	13
175	Ovary, Fallopian tube and broad		I.									a fair a							-		1
SUGE S	ligament	-	1	10-1-1	-	4	1	4	19	25	62	51	70	84	62	44	30	17	4	1	479
176	Other and unspecified female	PER	F				2 4			1					1					1	
E CAS	genital organs	-	-	-		-	-	-	3	3	7	9	7	20	15	32	23	17	12		148
	ATTRACT TO ATTACK OF THE ATTACK		and the	the first	and the second	1	1. 2. 2	- 12		1 2		1	23	2.5. 200	E I	- 64		Carlo and	ALC: N	-	1. 192

	190	Kidney	41	3	1	- 1	- 1	-1	21	1	4	4	6	8	10	15	6	10	1	6	-	81
		Bladder and other urinary organs	1	-		-	1	-	1	5	1	4	11	10	23	23	22	27	18	11	-	158
		Melanoma of skin	-	-	-	-	-	- 5	7	7	10	4	11	6	4	10	12	4	5	3	- 3	88 764
	191	Rodent ulcer	-	-	-	-	4	1	5	20	22	41	56	67	78 13	90 19	114 35	115 26	99 32	49 17	о 1	183
	191	Other malignant neoplasm of skin	-		1	-	-	-	1	1	62	7	11 2	14	15	19	30	20	-	-	-	15
	192	Eye	2		-	-	-	- 1	-	-	~	10	~		~	~	1 ×	7				·
	193.0	Brain - malignant neoplasm, other than glioma	_	_	_	_	_	1	1	-	-	-	1	2	1	1	-	-	-		-	7
	193.0	And a second	per la		er anti-		-			in the second	17	and the second second			and a second	and the second		and the second second				
	100.0	benign)	2	4	2	1	1	6	3	10	7	14	25	14	16	7	4	1	-	5	-	117 38
	223	Brain - benign neoplasm	5	1	2	-	-	1	1	2	5	-	5	- 8	4	3	-	-	1	-	-	20
	193.1-9	Other parts of nervous system -									2	4	5	4	6	3	4		_		1	मम
		any type of neoplasm	6	1	1	-	1	4	1	1	~	4	0	4	0	0	-			2 82		
	101	Thyroid gland	1		1	2	1	3	-	1	9	6	7	5	6	7	10	5	8	2	_	73
	194	Suprarenal gland - malignant			-	~	-							1								
	100.0	neoplasm	2	-	-	-	-	-	-	-	-	1		100 200	6 m -	-	0 7	1	-	-	-	4
	224	Suprarenal gland - benign neoplasm	-	-	-	-	-	-	-	-	-		-		-	-	-	-		-	-	-14
	195.1-8	Other endocrine glands - malignant	1								-				1				1		_	6
		neoplasm	1	-	-	1	-	1	-	-	. 1	-	1	-	-		-	en Phil		2		2
	224	Other endocrine glands - benign			-	-	-	1	_	_	1	_	2	1	1	-	-	-	-	à-	-	6
	196	neoplasm Bone	3	_	3	5	1	2	-	-	1	1	3	5	5	2	3	1	3	-	-	38
	197	Connective tissue	1	-	-	2	3	2	3	3	4	2	5	4	3	4	4	3	3	5	-	51
	198			1 de	14 14				See 1				the sec	1 10 10		100	18			3		20
		unspecified)	-	-	-	-	-	-	-	-	2	2	4	3 31	2 28	1 39	1 28	2 31	- 12	8	1	214
	199	Other and unspecified sites	-	-	1	-	-	-	1	2	2	13	11	51	60	09	20		1~	Ū	137	12 KD -+60
	000 0	Reticulum cell sarcoma	1	i de	1	1	18 _ 1	1	_	1	2	2	10	5	3	9	4	3	1	-	-	42
		Lymphosarcoma	1	1	1	-	-	1	2	2	1	-	4	5	4	5	9	4	3	3	-	46
	200.1		-	-	2	5	3	6	3	3	5	2	4	2	6	4	6	5	1	-	-	57
		Other forms of lymphoma		100	41.2			in pro	100					119	1919		1	7	-			24
		(reticulosis)	-	-	-	1	-	1	-	1	2	25	2 4	1	39	2 14	1 16	3 8	5 9	-	1	71
	203	Multiple myeloma (plasmocytoma)	- 3	- 8	- 3	- 1	- 1	-	-	-	- 1	1	6	3	3	2	10	2	1	-	-	36
2	04.3 part	Lymphatic leukaemia - acute	0	8	0	-	C T				-	-	0	U		~	1					- A Q
	204.0	Lymphatic leukaemia - chronic and unspecified	-	1	1	-	-	-	1	-		1	3	1	5	7	4	8	1	1	-	34
		unspectified		-																		56
2	04.3 part	Myeloid leukaemia - acute	1	-	2	2	2	1	5	1	7	3	3	4	9	1	4	6	5	-	1	50
	204.1	Myeloid leukaemia - chronic and										0	3	4	3	2	8	1	3	and a second	1	38
		unspecified	-	-	-	- 1	1	-	2 -	1	4	6 1	3 1	4	1	~ _	2	1	1	19 - 4	1	11
2	04.2 part	Monocytic leukaemia - acute Monocytic leukaemia - chronic and	-	-	-	T	1			-	-	-	-		-		~					the second
2	04.2 part	unspecified	-			-	-		-	-	-	-	1	-	-	1	-	-	-	-	-	2
2	04.3 part	Leukaemia - cell type not stated -		12-155	10	1	-	a the	10	1. 43		199			1000	are, i						12
~	The second states	acute	2	-	2	2	1	1	-		1		1	-	1	hanger and		-	1	-		12
	204.4	Leukaemia - other stated and												1	Sales Parties	and the second	2	_	1	1	-	6
		unstated cell type	-	-	-	1	-	-	-	-	-	-	-	1 ×			2			1 74		
20	0.2 & 205	Other lymphoid tissue and mycosis.		in the		_	100-	-	-	_	-	-	1	1	1	1	-	2	-	1	-	7
		fungoldes				1	N.C.												4			31
		Premalignant conditions - all sites	-	-	-	-	-	1	1	10	6	2	5	2	1	-	2	-	1	-	1	31
		Doubtful malignancy - all sites	-	-	-	-			-	-	-					36	(R		-			0 444
		All sites	37	20	26	26	29	65	160	289	534	773	931	1,078	1,176	1,260	1,250	1,013	655	329	15	9,666
PERSONAL PROPERTY OF	And and the Article of the Article of the Article of the		and the second se	DECTRONAL CONTRACTOR	and the second second	and the state	Section of the		1000 mar	and the second of the	Sector States											

## Appendix Table G.

# Cases of cancer of selected sites by age, sex and stage of growth. Percentages of cases staged

England and Wales, 1961

18/ 10 11/11

Appendix Table G. continued

							Age-grou	ıp				1.00		% of
Sta	ge	Sex	0-4	5–14	15-24	25–34	35-44	4554	55-64	65–74	75 and over	Age not stated	Total	% 01 all cas staged
							Мо	uth (ICD	Nos. 14	3 and 14	4)			
EPo		M F	-	-		2 1	2 3	14 6	19 18	24 13	21 17	-	82 58	34 44
EPs		M F	-5 <u>-</u> 5-5 1990		-	- 1			3 -	1	1 -	-	5 -	2 -
LP <sub>O</sub>		M F	-	-	1 1	-	1 1	4 3	10 4	19 16	26 8	-	61 33	26 25
LPs		M F	-	- 	-		1 -	5 4	12 2	24 7	25 8		67 21	28 16
Metastas present		M F	-	-		-	- 1	- 4	8 1	12 9	4 5		24 20	10 15
Total ca staged	ses	M F	- 		1 1	2 1	4 5	23 17	52 25	80 45	77 38		239 132	100 100
Stage no stated	t	M F		-	· - 1	- 3	4 5	9 10	34 18	43 30	56 23		146 90	
Total		M F	.s= 0 0	20) <b>-</b> 003	1 2	2 4	8 10	32 27	86 43	123 75	133 61	-	385 222	
							Pha		CD Nos. 1	45-148)				
EPo		M F	-	2 -	0- 10-	1	1 4	7 13	23 16	18 9	12 12	- 1	64 55	17
EPs		M F	-		1		17 11	ī	2 2	1 1	1 1	-	4 5	1 2
LPo		M F	1	1 -	-	2-	2 4	5 11	23 22	27 22	26 14	-	86 73	22 31
LP <sub>S</sub>		M F	-	2 -	2 -	1 2	7 7	15 11	64 27	42 24	45 14		178 85	47 36
Metastas present		M F	-	1 -	-		- 1	5 2	9 7	23 8	10 2	- 10 10 10	48 20	13
Total ca staged	ises	M F	=	6 -	2 -	4 2	10 16	32 38	121 74	111 64	94 43	-	380 238	100
Stage no stated	ot	M F	1 -	2 -	4 2	4 3	10 6	31 25	68 49	66 37	59 41	1	246 163	
Total		MF	1 -	8 -	6 2	8 5	20 22	63 63	189 123	177 101	153 84	1 1	626 401	
							Oeso	nhagus (	ICD No. 1	150)				
EPo		M	1	-				12	29	20	20	1 -	83	13
Other st	taged	F		-	-	2 3	3	7 33	23 112	25 116	21 125	-	81 394	10
cases w metasta	vithout ases	F		1_	-	2	12	27	62	114	110	1	328	6;
Metastas present		M F	-	-	-	1	6 5	28 20	56 21	67 34	31 37	-	189 117	21
Total ca staged	ases	MF	170	1	-	4 4	12 20	73 54	197 106	203 173	176 168	-	666 526	10 10
Stage no stated	ot	M F				1 3	5 7	45 38	85 42	138 78	121 101	1	396 270	
Total		м	-	1	_	5	17 27	11.8 92	282 148	341	297	1	1,062	-

4					1.11	Age-grou					1	- T	
Stage	Sex	0-4	5–14	15-24	25-34	35-44	4564	55-64	65-74	75 and over	Age not stated	Total	% of all cases staged
and the second second		The St.		inter a start	ation Bri		Lip	(ICD No.	140)	and a second	· · · · · · · · · · · · · · · · · · ·	R. Sok	हों है, जे स्ट्रा
EPo	M F	-	+ -	1	3-	16 1	'42' 6	71 6	82 9	54 16	-	268 38	83 93
EPs	M F	-	-			-	3	1			12	4	1
LPo	M	-	-	-	-	2	3	5	6 2	18 1	-	34	10
LPg	M	-	-	-	-	-	- 2	1	1	8	-	12	7 4
Metastases	F	-	-	-	-	-	- 1	200	- 2	- 3	-	- 6	- 2
present	F	-	-			-	-	-	-	-	-	-	
Total cases staged	F	-	-	Ξ	3	18 1	51 6	78 6	91 11	83 17	-	324 41	100 100
Stage not stated	M F		-	-	1	13 -	21 2	43 2	50 7	55 6	1	184 17	ale the
Total	M F	-	-	Ξ	4 -	31 1	72 8	121 8	141 18	138 23	1 -	508 58	1 - 1 - 1 - T
							Tongu	e (ICD No	. 141)				
EPo	M F	-	-	-	ī	4 1	8 7	12 7	14 19	19 18	-	57 53	29 50
EPs	M F		-	-	-	1	- 1		3	2 1	-	62	3
LP <sub>0</sub>	M F	1 1	+		-	2	4 3	3 4	12 4	12 6	-	33 17	16 16
LPg	M	1	+	1	_	5	4	15	21	41	_	88	44
Metastases	F	-	-	-	-	1 1	- 3	7 4	6 4	11 4		25 16	24 8
present Total cases	F	- 1	-	- .1	-	-	1 19	1 34	4 54	उ 78	-	9 200	8 100
staged	F	-	-		1	13 2	12	19	33	39		106	100
Stage not stated	M F	-	-	- 1000 - -	4 	3 3	17 5	31 9	40 18	43 25	-	138 60	and the second
Total	M F	1 -	с- 	1	4 1	16 5	36 17	65 28	94 51	121 64	-	338 166	
						Se	alivary	gland (10	CD No. 1	42)			
EPo	M F		1 2	5 2	16 12	12 14	9 18	9 27	6 12	6 13	-	64 100	61 69
EPs	M F	-			ī	-		<b>i</b>	1		-	- 2	- 1
LP <sub>o</sub>	M F	1 1	- 2	- 1	2 3	3 4	4 4	7 6	4	2 8	-	22 31	21 22
LP <sub>S</sub>	M F		-	-	- 1	7	1	2 1	6 2	1	-	10 5	10 4
Metastases	м	-	-	-	-	1	- 2 3	1	1	3		8	8
present Total cases staged	F M F		1 4	53	- 18 17	- 16 18	3 16 25	19 35	- 17 17	3 12 25	-	104 144	4 100 100
Stage not	M	-	1	4	8	17	24	15	23	9 11	- - 1	101 126	100
stated Total	F M	-	1 2	8 9	19 <b>26</b>	19 <b>33</b>	27 <b>40</b>	20 <b>34</b>	20 <b>40</b>	21	-	205	
	F	-	5	11	36	37	52	55	37	36	1	270	<u> </u>

Age-group Age not % of Stage Sex 75 Total all cases 0-4 15-24 25-34 5-14 35-44 45-54 55-64 65-74 and stated staged over Stomach (ICD No. 151) 272 202 M F 32 22 84 39 79 73 57 60 7 7 EPo 1 1 2 17 1 -8 Other staged 201 74 1,417 965 32 20 466 347 35 36 402 310 Μ --1 -6 cases without 194 -325 F metastases Metastases 76 785 360 772 560 1 1 2,354 58 Μ 2 14 352 352 -49 147 400 1,531 present -12 57 22 16 125 77 585 243 1,271 1,317 593 980 719 785 22 4,043 100 Total cases M -2 2,698 staged F -2 100 190 70 M F 51 21 1 419 492 1,494 Stage not 7 333 1 -11 172 345 392 1 1,012 stated -5,537 3,710 M F Total 1 2 29 176 775 1,690 1,809 1,052 33 -313 765 1,325 1,177 27 98 2 Small intestine, including duodenum (ICD No. 152) M F 13 8 EPo -16 -1 --2 -16 Other staged 26 19 32 M F cases without -1 8 1 2 --5 37 metastases 1 1 43 24 Metastases Μ -15 10 11 2 52 3 47 present F -4 9 5 Total cases M 26 7 27 19 82 51 100 -1 4 --12 -100 staged F 18 7 -M F 4 9 42 42 Stage not 15 10 --7 stated -1 11 10 -124 93 M F 33 13 42 29 29 22 Total 10 -1 8 1 11 16 1 Large intestine, except rectum (ICD No. 153) 368 501 EPo M F 53 99 118 89 -4 1 17 -123 157 121 -1 22 65 -17 Other staged M F 31 39 76 125 190 216 248 223 - -777 36 cases without -358 362 1,110 37 metastases 10 15 36 49 256 327 326 442 1,012 1,379 M F 135 248 47 Metastases - 2 -1 165 378 46 present -71 110 545 666 2,157 2,990 M F 23 31 264 355 690 957 1 2 Total cases -560 100 37 861 1 100 staged 1,232 1,569 M F Stage not -15 47 133 292 403 335 stated -3 14 18 69 176 331 490 465 3 118 179 397 531 837 1,093 895 997 1,447 1,326 3,389 4,559 M F 38 49 Total -10 1 5 4

Appendix Table G. continued

20.2			nin ni	and the second			Age-grou	10					. [	
Stage	intal.	Sex	0-4	5-14	15-24	25-34	35-44	45-54	55-64	65-74	75 and over	Age not stated	Total	% of all cases staged
				1.11.16	93 .off	Caecu	m, append	ix and a	ascending	colon	ICD No.	153.0)		
EPo		M F	-	- 1	-3	1 3	2 5	9 13	22 23	17 30	14 31	-	65 109	17 16
Other staged cases witho metastases		M F	-		ī	4 1	8 9	18 19	32 42	50 75	41 104		153 251	39 38
Metastases present		M F	-		1	2 1	6 6	14 24	36 66	57 103	54 109	-	170 310	44 46
Total cases staged		M F	-	-	1 5	7 5	16 20	41 56	90 131	124 208	109 244	- E 4	388 670	100 100
Stage not stated	986 986	M F	-	- 3	3 12	9 8	12 12	27 32	63 66	83 123	71 136	- 1	268 393	Take start
Total		M F	-	- 4	4 17	16 13	28 32	68 88	153 197	207 331	180 380	- 1	656 1,063	- income
Transverse colon, including hepatic and splenic flexures (ICD No. 153.1)														
EPo		M F	-	-	- 100 -	1 1	1 1	13 14	15 21	18 24	11 17	-	78	18
Other stage cases with metastases	out	M F		-	11218 <u>-</u>	1 3	4 7	10 16	26 26	29 68	29 41		99 161	33 38
Metastases present		MF	-		853 <u>-</u> 828 <u>-</u>	2 4	4 11	20 26	32 44	43 53	40 51	- 5	141 189	47 44
Total cases staged		M	-		2860 <u>-</u>	4 8	9 19	43 56	73 91	90 145	80 109	=	299 428	100 100
Stage not stated	2.12. 1991	MF	-		1	3 2	8 10	20 24	44 46	66 80	34 58	- 1	176 221	Alexandria (
Total		M	-		1 1	7 10	17 29	63 80	117 137	156 225	114 167	- 1	475 649	1345
										100	4 59 91			
							De		Colon (			1 1 4	29	23
EPo		M F		-	-	1	1 3	7 3	5 7	10 13	5 5	-	31	18
Other stag cases with metastase	lout	MF	1.1	0.8 <u>-</u> 2.0	1		- 4	1 8	12 12	16 16	12 19		42 60	33 34
Metastases	22 70	MF	1.1	0 82 -		- 2	'3 4	7 11	15 18	23 25	7 25	- H	55 85	44 48
Total case staged	5 978	M	1-1-	- 15		1	4 11	15 22	32 37	49 54	24 49		126 176	100 100
Stage not	100 123	M	1-1	121 - 122 -	102	3			17 20	15 32	24 28	-	66 106	The saw
stated Total		M	-	- 22	11 11	L 1 - 6			49 57	64 86	48 77	-10	192 282	alex.
				1	-		-	-						

21

## Appendix Table G. continued

				-			Age-grou	up				Age not	Total	% of all cases
Stage	Toral	Sex	0–4	5-14	15-24	25-34	35-44	45–54	55-64	65-74	75 and over	stated	Tota I	staged
							Si	gmoid Col	on (ICD	No. 153.	.3)			
EPo	23) 664	M F	-	р. <del>с.</del> 10 <del></del>	100 <b>-</b>	2 2	- 7	12 18	40 41	45 40	36 39		135 147	21 19
Other staged cases witho metastases		M F	- -	115 3075		- 2	5 10	21 36	55 65	70 91	58 63		209 267	32 34
Metastases present	68°2 1982	M F	-	4.5 1.7		1 4	15 15	46 57	86 92	89 126	66 72		303 366	47 47
Total cases staged	1月1日之 日本社	M F	-			3 8	20 32	79 111	181 198	204 257	160 174		647 780	100 100
Stage not stated	ARANS REPART	M F	-	27- 015	2 1	1 2	10 21	49 60	83 98	127 107	108 109	- 1	380 399	jaber azetti.
Total	1455 1650 , 1	M F	=		2 1	4 10	30 53	128 171	264 296	331 364	268 283	ī	1,027 1,179	1490
	euspis .							Rectum	(ICD No.	154)				
EPo		M F	-	1	44 - 45 -	5 1	9 15	55 43	144 92	152 122	95 71		461 344	22 21
Other staged cases without metastases	ut	M F	-	40- 30-	3 2	6 4	20 17	74 73	210 135	253 192	226 213		792 636	39 40
letastases present	1.445 (1.464)	M F	-		2 -	8 3	29 26	100 96	237 136	238 219	178 146	1	793 626	39 39
Total cases staged	483 865	M F	- -	1	5 2	19 8	58 58	229 212	591 363	643 533	499 430	1	2,046 1,606	100 100
Stage not stated	and a	M F	-	187 - K	- 2	3 17	34 35	136 115	312 222	400 300	325 289	1	1,211 981	adamananan Tun usurr
lotal	070 646	M F	- 1	1	5 4	22 25	92 93	365 327	903 585	1,043 833	824 719	2 -	3,257 2,587	(asut
							Live	er (prima	ry) (ICD	No. 155	.0)			
P <sub>o</sub>		M F	- 1	4 = 1 1 = 1	24 - 1 1	1	- 1	1 1	2 1	3 1	-	E	7 5	5 6
)ther staged cases withou metastases	ıt	M F	3 -	sa - ba -	- 1	1	4 2	12 6	27 9	22 9	10 10		79 37	53 41
letastases present	200 200	M F	2 1	- 1	2	2 -	3 2	6 5	24 15	18 11	8 12	-	63 47	42 53
otal cases staged		M F	5 2	- 1	ī	<b>4</b> -	7 5	19 12	53 25	43 21	18 22	=	149 89	100 100
stage not stated	040 20.2	M F	1 3	1 1	- 1	3 -	8 3	10 4	28 8	29 22	12 19	- * .	90 61	don space
otal	102	M	6 5	1 2	-2	7	15 8	29 16	79 33	72 43	30 41	-	239 150	- AND - AND

Sex Stage EPo M F Other staged cases without M F metastases M F Metastases present H Total cases staged M F Stage not stated M F Total M F EPo Other staged cases without M F metastases M F Metastases present M F Total cases staged M F Stage not stated M F Total M F EPo M F EPs LPo M F LPS M F M F Metastases present M F Total cases staged M F Stage not stated MF Total

				Age-gro	חווו	The second second					
0-4	5-14	15-24	25-34	35 <del>-</del> 44	45 <b>-</b> 54	55-64	65 <del>~</del> 74	75 and over	Age not stated	Total	% of all cases staged
1100	Carl Jones	G	allbladd	er and e	xtra-hep	atic gal	l ducts	Con the second	155.1)		
-	-	-	-	* 2	3	8 7	5 14	5 13		21 38	9 10
-	- 8		1	~	9	19 17	18 39	12 35	- 1	59 98	27 27
	-	-	2	Б 3	23 13	36 47	51 89	24 77	-	141 230	64 63
Ē	-	-	3	5 5	35 21	63 71	74 142	41 125	- 1	221 366	100 100
-	-	-	<b>-</b> 1	3 2	8 14	22 38	38 80	29 55	+	100 190	Distant and
- 8	=	-	3 2	8 7	43 35	85 109	112 222	70 180	ī	321 556	Self stages
						s (ICD N					\$8263
-			- - -		7 3	8 8	21 14	10 7	1	47 32	4 3
-	<b>~</b> 1		1 2	9 3	43 22	95 79	108 95	85 97	-	341 299	31 33
	:	1 1	1 3	28 18	101 60	217 150	234 205	128 142	1	709 579	65 64
- 78	- 1	1	2 5	37 21	151 85	320 237	363 314	221 246	2 _	1,097 910	100 100
- 12	-	-	-	14 3	51 38	123 76	151 157	122 150	1 1	462 425	State of the
-8	- 1	1 1	2 5	51 24	202 123	443 313	514 471	343 396	3	1,559 1,335	-rabansansu -rabansansu
				Nasa	al Sinuse	es (ICD )	lo. 160 j	part)			
-	-	- 10	-	1	2	9	3	5	-	20	34
1 2.6	~	there is a	lege to a lege	3	1	2	1	4		11	23
-	-	-	-	-	-	-	+	-	-	100	
	() <u>-</u> ()	-	be 13-00	1	5 3	8 3	7 8	4 8	-	24 21	41 45
-	Ξ	:		-	1 1	1 2	1 1	2	-	36	5 13
-	-	:	-	<b>.</b> 1	3 1	1 3	3 3	5 1	*	12 9	20 19
	Ξ	102 - -	- 192	1 5	11 6	19 10	14 11	14 15	-	59 47	100 100
	2	* 1	-	3 4	5 2	14 8	13 14	11 11	*	46 40	Street Last
- 10	-	- 1		4 9	16 8	33 18	27 25	25 26	-	105 87	Ganderer Received Contra

.

#### Age-group Age not % of 75 not and stated Total all cases Stage Sex 0-4 5-14 15-24 25-34 35-44 45-54 55-64 65-74 staged over Glottis, true vocal cords (ICD No. 161 part) EPo Μ 146 12 -25 51 1 44 20 1 -71 F -2 5 3 1 -67 EPs Μ 1 1 1 2 5 2 - 1 ----LPo Μ 7 15 15 41 32 20 -F 3 --6 33 LPs M 3 9 5 3 2 -F \_ Metastases M F 1 1 -3 -5 2 present ----Total cases 35 2 MF 71 8 64 1 28 206 18 -100 staged --11 -1 5 100 Stage not M F 129 8 --10 24 41 40 13 -stated --2 1 1 -1 Total M F 335 26 ---16 59 112 104 41 ---4 9 2 6 Larynx (except true vocal cords) (ICD No. 161 remainder) 110 13 EPo M F 31 19 38 12 36 28 -8 -4 1 3 3 EPs M 0 1 -1 ----LPo MF 87 17 31 17 1 29 8 25 4 -2. 7 5 3 36 LPS M F 80 11 31 21 4 12 11 1 27 1 2 3 1 4 - 2 23 Metastases M F 10 23 2 -8 -6 5 present 3 -13 2 1 Total cases 101 13 93 9 MF 45 11 16 41 2 301 47 100 staged 2 11 100 ---Stage not M F 78 60 36 1 1 216 32 -34 13 stated --4 3 6 5 153 22 Total M F 23 75 179 81 14 2\_\_\_ 517 79 -3 15 19 Bronchus and Lung, (specified as primary) (ICD No. 162.1) M F EPo 76 13 11 7 34 13 186 523 363 1,185 -3 -127 35 26 -38 --2 EPs M F 119 17 1 1 62 10 20 32 -3 2 -1 3 3 3,455 LPo M F 31 28 12 75 440 1,274 1,210 438 5 1 84 524 1 5 27 82 158 167 -LPs M F 12 88 30 368 73 710 438 59 88 30 2 1,708 16 -2 4 84 280 15 -M F 164 51 1,295 268 342 124 Metastases 17 879 1,806 2 -4,509 3 41 1 present 8 164 280 895 49 44 19 1,905 348 3,326 532 946 251 MF 364 122 Total cases 10 4,375 5 10,976 100 staged 1 -570 1,843 100 --M Stage not 21 579 10 5,189 -1 142 800 1,987 1,649 stated 1 125 213 270 178 1 843 2,705 473 6,362 4,975 1,525 783 802 429 M F 506 173 15 16,165 1 2,686 Total 1 2 65 23 11

### Appendix Table G. continued

Stars	Sex	1. mar			A land of the second second	Age-gro	pup	ala series de la compañía de la comp		Ma	Age	a line and	% of
Stage	Sex	0-4	5-14	15-24	25-34	35-44	45 <del>-</del> 54	55-64	65-74	75 and over	not stated	Total	all cases staged
						Br	east (IC	No. 170	)				
EPo	M F	-	-	-3	1 .53	<b>2</b> 45	2 489	5 431	6 371	2 221	3	16 1,816	25 33
SP <sub>s</sub>	M F	-	Ξ	-	28	152	1 224	4 224	3 189	76	- 2	8 895	12 16
LPo	M F	-			8	- 42	- 99	1 111	5 131	3 150	-	9 542	14 10
LPS	M F	-	-	1	20	- 145	3 289	6 311	6 253	5 210	- 3	21 1,231	33 23
vetastases present	M F	-	-		- 15	- 68	3 201	5 225	1 243	1 200	-3	10 955	16 18
Total cases staged	M F	-	in E da	1 3	1 124	- 652	9 1,302	21 1,302	21 1,187	11 857	 12	64 5,439	100 100
Stage not stated	M F		w = 1	- 2	- 57	3 250	8 455	8 478	9 449	9 <b>336</b>	- 4	37 2,031	ADA HAR Double
Total	M F	=	0. <u>i</u> 0 -	1 5	1 181	3 902	17 1,757	29 1,780	30 1,636	20 1,193	 16	101 7,470	1pr
			literu	e narte	enecifi	ied and u	unspecifie	d excel	at carvis	( 100 N	05 172-	178)	
IP <sub>o</sub>	F	-	-	2 2	5	54	231	316	186	71	-	865	51
other staged cases without		1 1-											
metastases	F	-		-	3	24	78	159	125	75	-	464	27
letastases present	F	-	-	3	2	22	64	130	95	55	1	372	22
Total cases staged	F	_ 3	_ *	5	10	100	373	605	406	201	1	1,701	100
Stage not stated	F	- 19	*	2	8	61	229	356	260	126	2	1,044	a carro
lotal .	F	-	-	7	18	161	602	961	666	327	3	2,745	Jon to
				Ovar	y, Fallo	opian tul	be, and bi	road liga	ament (10	CD No. 1	.75)		
Po	F	-	1	6	10	32	82	91	42	30	-	294	14
other staged cases without metastases	F	18	2	4	7	38	91	140	97	42	1	422	21
letastases present	F	-	1	7	17	107	323	400	318	149	4	1,326	65
otal cases staged	F	- 1	4	17	34	177	496	631	457	221	5	2,042	100
stage not stated	F	-	-	11	24	85	185	197	160	88	1	751	- Ballynes an
Total	F		4	28	58	262	681	828	617	309	6	2,793	A REAL PROPERTY OF

54

-

## Appendix Table G. continued

Stage

Other staged cases without

metastases

Metastases present

Total cases staged

Stage not stated

Total

EPo

Other staged cases without

metastases

Metastases

Total cases

present

staged

Stage not stated

Total

EPo

EPs

LPo

LPs

Metastases present

Total cases

staged

Stage not stated

Total

EPo

Sex

M F

M F

M F

M F

M F

M F

M F

M F

M F

M F

M F

M F

M F

M F

M F

M · F

M F

M F

M F

M 23 F 21

HP <sub>g</sub> N     -     -     -     -     -     3     15     10     10     -     15     60       Idstantanes     M     -     -     -     -     -     4     30     140     348     344     1     876     30       Idstantanes     M     1     -     -     -     -     5     58     345     916     1,062     2     2,409     100       State of tabe     M     1     -     -     -     -     6     65     543     1,409     1,651     4     5,691       State of tabe     M     1     -     -     -     -     6     65     543     1,409     1,651     4     5,691       State of tabe     M     2     1     15     45     31     44     12     -     -     12     12       Fo     M     -     -     1     1     -     -     -     12     13     14     1     1     -     -     13     14     14     15     16     17     13       Fo     M     -     -     1     15     14     16     1     15     16	for the second	and an and a series		edite state								-	£	1	
Protectic (1CD No. 177)           SP0         H         -         -         -         -         -         103         2200         2833         1         743         31           SP0         H         -         -         -         -         103         2200         2833         1         743         31           SP0         H         -         -         -         -         1         3         7         -         11         1           SP0         H         -         -         -         -         -         3         45         50         300         50         7         -         73         33         22           GallAndes         H         -         -         -         -         -         3         45         50         345         344         1         676         30           Stated         H         1         -         -         -         1         277         198         683         700         8         1,681         1         3,990           Stated         H         1         2         -         -         1         277         198<	Stage	intel	Sex	0-4	5–14	15-24	25-34	Sector Contraction of the sector	and the second second second	55 <del>.</del> 64	65-74	and	not	Total	all cases
BF0       H       -       -       -       -       17       103       200       383       1       793       31         BF2       H       -       -       -       -       -       -       103       200       383       1       793       31         BF2       H       -       -       -       -       -       1       0       77       280       380       -       726       30         BF3       H       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -	Australia		Strategy in				and the second sec		Prostate	e (ICD No	. 177)	0,01	and the second second	Le construction de la construcción de la construcci	and the second second
Page       N       -       -       -       -       -       1       3       7       -       11       1       1         Page       N       1       -       -       -       1       0       77       220       309       -       726       300         Page       N       -       -       -       -       -       -       3       15       15       15       10       -       726       300         Page       N       -       -       -       -       -       -       1       5       59       345       916       1.062       2       2.409       100         Page       N       1       -       -       -       1       27       100       563       709       2       1.581       100       100       100       100       100       100       100       100       100       100       1.55       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58       1.58	EP	( and a l	М		_	-	-	-				323	1	743	31
$a^{a}$ H       I $a$ $a$ $a$ $1$ $a$ $77$ $220$ $369$ $a$ $726$ $300$ $aF_{a}$ H       I $a$		6.20, 3		1 H								+			
o       M       -       -       -       -       3       15       16       10       -       83       2         defaminations stages       M       -       -       -       -       3       15       16       10       -       83       2         defaminations stages       M       1       -       -       -       -       5       58       945       916       1,082       2       2,409       100         Stage not stated       M       1       -       -       -       -       5       58       945       916       1,082       2       2,409       100         Stage not stated       M       1       -       -       -       -       1       27       106       563       700       8       1,551       4       3,990       1         Protein       M       2       1       15       45       31       14       12       3       3       3,990       1       153       4       53       3       3,990       1       153       15       163       163       163       163       163       163       163       163       163       163<	EPs		M	-	-	 1012	н 1993 — 1993	1	-	1	3	7		11	1
$^{\circ}$ H $                                                                                              -$ </td <td>LP<sub>O</sub></td> <td>N</td> <td>M</td> <td>1</td> <td>-</td> <td>-</td> <td>- -</td> <td>1</td> <td>8</td> <td>77</td> <td>250</td> <td>389</td> <td>- 4</td> <td>726</td> <td>30</td>	LP <sub>O</sub>	N	M	1	-	-	- -	1	8	77	250	389	- 4	726	30
на         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -	LPs		M	-	-	-	-	- 	3	15	16	19	15	53	2
вtaged         M         1         -         -         -         5         58         345         916         1,022         2         2,409         100           Stage not stated         M         1         -         -         -         1         27         108         563         769         2         1,581           Fotal         M         2         -         -         -         6         85         549         1,499         1,651         4         3,990         1           Fotal         M         2         1         15         45         31         14         12         3         3         -         126         55           FP <sub>3</sub> M         -         -         -         1         1         -         -         -         16         3         3         3         3         3         -         126         13         16           AP <sub>3</sub> M         -         -         12         20         9         3         3         3         2         -         52         22           P <sub>5</sub> M         -         12         16         58         34<	Metastases present	9.2 2000	М	-	-		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	4	30	149	348	344	1	876	36
а tatated       M       1       -       -       -       1       27       108       683       709       2       1,561         Total       M       2       -       -       -       6       85       543       1,499       1,851       4       3,990         Testis (ICD No. 178)         Testis (ICD No. 178)         SP <sub>0</sub> M       2       1       15       45       31       14       12       3       3       -       126       55         SP <sub>0</sub> M       -       -       -       1       1       -       -       -       -       126       65         SP <sub>0</sub> M       -       -       1       6       4       4       2       1       1       -       -       37       16         AP <sub>0</sub> M       -       -       1       6       4       4       2       1       18       16       11       1       18       16       13       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3       3	Total cases staged		м	1	a - 1	13- 184 (7	283 1991	5	58	345	916	1,082	2	2,409	100
Notal         M         2         -         -         6         85         543         1.499         1.651         4         3.990           BP0         M         2         1         15         45         31         14         12         3         3         -         126         55           BP0         M         -         -         -         1         1         -         -         -         126         55           AP0         M         -         -         -         1         1         -         -         -         -         126         55           AP0         M         -         -         -         1         1         -         -         14         0         44         2         1         1         -         152         16         16         26         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16         16	Stage not stated	33	м	1	-	-		1	27	198	583	769	2.	1,581	The exact
Testis (ICD No. 178)         BP0       M       2       1       15       45       31       14       12       3       3       -       126       55         BP0       M       -       -       -       -       -       -       -       -       2       1         P20       M       -       -       -       1       1       -       -       -       -       2       1         P20       M       -       -       3       8       14       6       4       2       1       1       -       -       37       16         P30       M       -       -       1       8       4       4       2       1       1       -       19       8         Getataceses       M       -       -       12       20       9       3       3       1       10       206       10       10       10       10       10       10       10       10       10       10       10       10       10       10       10       10       10       10       10       10       10       10 <th10< th="">       10       10</th10<>	Total	and we de		ALC: NO	-									1.00	general de
Po       M       2       1       15       45       31       14       12       3       3       -       126       53         Po       M       -       -       -       1       1       -       -       -       -       2       1         Po       M       -       -       -       -       -       -       -       2       1         Po       M       -       -       3       8       14       6       4       2       -       -       2       1         Po       M       -       -       12       20       9       3       3       3       2       -       52       22         Itestatases       M       -       -       12       20       9       3       3       3       2       -       52       22        Itestatases       M       -       -       12       20       9       3       3       14       10       1       1       206       1       206       1       206       1       442       1       1       1       1       1       1       1       1       1		1 8112 VI	State State	1 23						net.					I constru
O       M       -       -       -       1       1       -       -       -       -       2       1         aPo       M       -       -       3       8       14       6       4       2       -       7       18         aPo       M       -       -       1       6       4       4       2       1       1       -       77       18         aPo       M       -       -       12       20       9       3       3       3       2       -       82       22         atases       M       -       -       12       20       9       3       3       3       2       -       82       22         atage not       M       1       2       23       69       57       31       13       4       5       1       206       2       22       100       3       11       1       442       12       16       16       28       -       77       54         atage not       M       1       2       23       69       57       31       13       1       1       420       17 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Testis</td><td>(ICD No.</td><td>178)</td><td></td><td></td><td></td><td></td></td<>									Testis	(ICD No.	178)				
$3$ $1$ $  3$ $8$ $14$ $6$ $4$ $2$ $  37$ $133$ $4P_g$ $H$ $  1$ $6$ $4$ $4$ $2$ $1$ $1$ $ 19$ $8$ $4etastases$ $H$ $  12$ $200$ $9$ $3$ $3$ $3$ $2$ $1$ $1$ $ 12$ $200$ $9$ $3$ $3$ $3$ $2$ $1$ $1$ $2$ $11$ $80$ $59$ $27$ $21$ $9$ $6$ $ 52$ $82$ $20tal$ $13$ $20$ $9$ $3$ $3$ $54$ $140$ $206$ $11$ $206$ $11$ $206$ $1141$ $1$ $206$ $1141$ $206$ $1141$ $206$ $1141$ $206$ $1141$ $206$ $1142$ $206$ $1142$ $1142$ $1142$ $1142$ $1142$ $1142$ $1142$ $116$ $116$ $286$	EPo	806	M	2	1	15	45	31	14	12	3	3	- <b>-</b>	126	53
O       M       -       -       1       6       4       4       2       1       1       -       19       8         itetastases present       M       -       -       12       20       9       3       3       3       2       -       52       22         Itetastases staged       M       -       -       12       20       9       3       3       3       2       -       52       22         Itetastases staged       M       2       1       31       80       59       27       21       9       6       -       52       22         Itetastases       M       1       2       23       69       57       31       13       4       5       1       206         Itetastases       M       1       2       23       69       57       31       13       4       5       1       206         RPo       M       1       2       23       69       57       31       13       31       1       442         RPo       M       -       -       -       1       -       1       3       4 <th< td=""><td>EPs</td><td></td><td>M</td><td>-</td><td>-</td><td>-</td><td>1</td><td>1</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>2</td><td>1</td></th<>	EPs		M	-	-	-	1	1	-	-	-	-	-	2	1
3       M       -       -       12       20       9       3       3       3       2       -       52       22         Iotal cases staged       M       2       1       31       80       59       27       21       9       6       -       236       100         Stage not stated       M       1       2       23       69       57       31       13       4       5       1       206         Stage not stated       M       1       2       23       69       57       31       13       4       5       1       206         Stage not stated       M       1       2       23       69       57       31       13       4       5       1       206         Fotal       M       3       3       54       149       116       58       34       13       11       1       442         Pro       M       -       -       -       4       2       12       15       16       28       -       77       54         Pro       M       -       -       -       -       1       3       4       10	LPo	444	М			3	8	14	6	4	2	-	-	37	16
present       M       -       -       12       20       9       3       3       3       2       -       52       22         Fotal cases staged       M       2       1       31       80       59       27       21       9       6       -       236       100         Stage not stated       M       1       2       23       69       57       31       13       4       5       1       206       100         Stated       M       1       2       23       69       57       31       13       4       5       1       206       100         Stated       M       1       2       23       69       57       31       13       4       5       1       206         Fotal       M       1       2       23       69       57       31       13       11       1       206       100         Fotal       M       1       2       23       16       16       28       7       7       54         State       M       -       -       -       1       3       3       3       3       3       3	LPS	382	M	-	-	1	6	4	4	2	1	1	2 - 3	19	8
staged       M       2       1       31       80       59       27       21       9       6        236       100         Stage not stated       M       1       2       23       69       57       31       13       4       5       1       206         Fotal       M       3       3       54       149       116       58       34       13       11       1       442         Stage not stated       M       3       3       54       149       116       58       34       13       11       1       442         Stage not stated       M       -       -       -       4       2       12       15       16       28       -       77       54         Stage not       M       -       -       -       1       -       1       2       -       -       4       3         SP <sub>0</sub> M       -       -       -       1       3       4       10       6       -       24       17         P <sub>0</sub> M       -       -       -       1       2       2       10       7       9	Metastases present	2017	M			12	20	9	3	3	3	2		52	22
statedM122369573113451206FotalM3354149116583413111442Penis (ICD No. 179.0)Penis (ICD No. 179.0)Penis (ICD No. 179.0) $2P_0$ M42121628-7754SP8M1-1243 $P_0$ M134106-7754 $SP_8$ M134106-743 $P_0$ M1334106-2417 $P_8$ M12210779-3122PresentM1-311-64Total cases stagedM5717333644-142100	Total cases staged	100.1	M	2	1	31	80	59	27	21	9	6		236	100
FotalM3354149116589413111442Penis (ICD No. 179.0) $P_0$ M4212151628-7754 $P_0$ M1-1243 $P_0$ M134106-2417 $P_0$ M12210779-43 $P_0$ M12210779-43 $P_0$ M12210779-43 $P_0$ M1-311-64 $P_8$ M1-311-64Total casesM5717333644-142100Bage not statedM1919222927-107	Stage not stated	10.00	м	1	2.	23	69	57	31	13	4	5	1	206	Tesel
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			12.20-33											124	
Penis (ICD No. 179.0) $BP_0$ M       -       -       -       4       2       12       15       16       28       -       77       54 $BP_s$ M       -       -       -       -       1       -       14       3 $AP_o$ M       -       -       -       -       1       3       4       10       6       -       24       17 $AP_o$ M       -       -       -       1       2       2       10       7       9       -       24       17 $AP_s$ M       -       -       -       1       2       2       10       7       9       -       91       22         If etastases present       M       -       -       -       -       3       1       1       -       6       4         Iotal cases       M       -       -       -       5       7       17       33       36       44       -       142       100         Bage not       M       -       -       -       1       9       19       22       29		i sase											22 1 3		
$G^{0}$ M       -       -       -       1       -       1       2       -       -       4       3 $P_{0}$ M       -       -       -       1       3       4       10       6       -       24       17 $P_{0}$ M       -       -       -       1       3       4       10       6       -       24       17 $P_{S}$ M       -       -       -       1       2       2       10       7       9       -       31       22         Metastases       M       -       -       -       -       1       -       3       1       1       -       6       4         Total cases       M       -       -       -       5       7       17       33       36       44       -       142       100         Stage not stated       M       -       -       -       1       9       19       22       29       27       -       107       -									Penis (	ICD No. 1	179.0)				
$BP_s$ M1-1243 $P_0$ M134106-2417 $P_s$ M1221079-3122 $P_s$ M1-311-64 $P_s$ M1-311-64 $P_s$ M5717333644-142100 $P_s$ M1919222927-107	EPo		M	-	-	-	4	2	12	15	16	28	-	77	54
$P_0$ M       -       -       -       1       3       4       10       6       -       24       17 $P_S$ M       -       -       -       1       3       4       10       6       -       24       17 $P_S$ M       -       -       -       1       2       2       10       7       9       -       31       22         Interstances       M       -       -       -       1       -       3       1       1       -       6       4         Interstance       M       -       -       -       -       1       -       3       1       1       -       6       4         Interstance       M       -       -       -       5       7       17       33       36       44       -       142       100         Stage not stated       M       -       -       -       1       9       19       22       29       27       -       107	EPs	134	М		-	-	_	1	-	1	2	-	-	3 4	3
Interastases present       M       -       -       -       1       -       -       6       4         Interastases present       M       -       -       -       1       -       -       6       4         Interastases present       M       -       -       -       1       -       -       6       4         Interast       M       -       -       -       5       7       17       33       36       44       -       142       100         Stage not stated       M       -       -       -       1       9       19       22       29       27       -       107	LPo	682.U	М	- 0.0	4 <u>-</u> 4	42	(2)24 1244 -	1	3	4	10	6		24	17
present       M       -       -       -       1       -       3       1       1       -       6       4         Total cases staged       M       -       -       5       7       17       33       36       44       -       142       100         Stage not stated       M       -       -       -       1       9       19       22       29       27       -       107	LP <sub>S OPE</sub>	2.40.3	м	- 18	a - 1	(3)6 -	1	2	2	10	7	9		31	22
Total cases staged       M       -       -       5       7       17       33       36       44       -       142       100         Stage not stated       M       -       -       -       1       9       19       22       29       27       -       107	Metastases present	14	м	00	_	5450. <u>-</u>	- 198	1	-	3	1	1	r [] a	6	300 mm
Stage not stated M 1 9 19 22 29 27 - 107	Total cases	1917.43	1	99	¢ _	128 12			17			*		11	Casal.
	Stage not stated		м	_	-		1	9	19	22	29	27		107	
	Total		M				6	16	36	55	65	71		249	

56

200	Ter Street		and the second second		Age-gro	up				Age		% 01
x	0-4	5-14	15-24	25-34	35-44	45-54	55-64	. 65-74 .	75 and over	not stated	Total	all cases staged
nte-	a. 143	tury bit	e epoquel	Star Star	Side of the	Kidney	(ICD No.	180)				
	6 1	1 2	2 1	2 1	8 3	29 11	34 15	.24 17	13 11	-	119 62	21 18
	3 4	1	2 1	3 3	14 6	39 10	51 25	35 30	19 27	- 2	167 108	30 31
	6 9	1 2	- 2	2 3	11 11	42 19	98 62	74 38	36 28		270 174	49 51
-	15 14	3 4	4 4	7 7	33 20	110 40	183 102	133 85	68 66	-2	556 344	100 100
5.0	8 7	1 2	1 1	1 2	16 8	66 29	85 35	76 44	57 56	2 -	313 184	
1	23 21	4 6	5 5	8 9	49 28	176 69	268 137	209 129	125 122	22	869 528	
				Bladder	and othe	r urinar	y organs	(ICD No.	. 181 p	art)		
in an	- 1	-	1 1	3 4	26 10	94 22	222 54	200 68	128 54		674 214	42 36
		- -	-	4 -	14 5	64 30	168 54	282 97	233 95	1 -	766 281	47 48
		- -	-	1 -	4 3	16 3	53 19	53 44	45 28		172 97	11 16
2.20	- 1	-	1 1	8 4	44 18	174 55	443 127	535 209	406 177	1	1,612 592	100 100
10	2 1		2 -	5	31 5	136 50	336 95	456 140	293 161	5 1	1,266 453	la construit
	2 2		3 1	13 4	75 23	310 105	779 222	991 349	699 338	6 1	2,878 1,045	
				Ma	alignant	Mel anoma	ı of skin	(ICD No	. 190)			
	-	2 -	2 9	6 22	8 29	14 38	9 24	10 30	9 29	=	60 181	<b>45</b> 68
[	1			- 1	11 (1 <u>1</u>	- 3	2 -	2 -	-2		4 6	3 2
[		-	1,	- 4	2 6	2 2	1 3	4 2	5 7	-	15 24	11 9
1	·	-	1 2	8 4	2 10	4 4	6 5	4 10	6 3	1.1	31 38	24 14
	-	-	-	4 2	3 2	1 3	9 2	3 5	3 3		23 17	17 7
-	-	2	4 11	18 33	15 47	21 50	27 34	23 47	23 44	- 14	133 266	100 100
1	1 -	1 1	2	4 23	17 43	24 37	22 32	9 35	13 26		91 199	TRANSPORT
1	1 -	3 1	4 13	22 56	32 90	45 87	49 66	32 82	36 70	100 - 14 100 - 14	224 465	1

## Appendix Table G. continued

- Maria and a second second			alan alarta da			State of the second	Age-gro				the second second	Age	and the second second	% of
Stage	Thent	Sex	0-4	5-14	15-24	25-34	35-44	45-54	55-64	65-74	75 and over	not stated	Total	all cases staged
		0	ther r	nalignar	nt neopla	usm of s	kin (all	sites ex	cept bre	ast and	genital	organs)	(ICD No.	191 part)
EPo	932 25	M F	-	- 1	- 1	3 6	45 13	95 47	167 85	212 128	262 173	4 1	788 455	79 78
EPs	V#2. 941.	M F		5	-	-	1 -	3 1	2 1	5 3	4 2		15 7	2 1
LPo	CATE .	M F		5	1	2 -	3 1	13 2	21 16	37 20	53 32	- 14 - 14	130 71	13 12
LPS	2058) 2020	M F	-	- 1	-	-	2 -	6 3	10 6	11 12	16 13		45 35	4 6
Metastases present	1934) 1934) 1963	M F	-		-	-	3 1	5 2	3 2	7 5	5 7	-	23 17	2 3
Total cases staged	1624) - 1722 -	M F	-	-2	1	5 6	54 15	122 55	203 110	272 168	340 227	4 1	1,001 585	100 100
Stage not stated		M F	-	ī	2-	3 1	12 17	62 36	112 49	169 92	199 136	1 1	560 333	
Total	878 122	M F	-	3	3 1	8 7	66 32	184 91	315 159	441 260	539 363	5 2	1,561 918	(and
Eye (ICD No. 192)														
EPo	THE .	M F	10 6	1	- 1	5 1	6 7	10 7	12 4	3 10	3 8	1	50 44	67 73
Other stage cases with metastases		M F	6 1	1 -		- 1 1411 -	2 -	2 1	2 4	6 5	2 2		21 13	28 22
Metastases present	1000 ( 1) 1000 ( 1)	M F	2 -	-	-	-	- 1	- 1	1 1	1 -		-	4 3	5 5
Total cases staged	1978 S.	M F	18 7	1	ī	5 1	8 8	12 9	15 9	10 15	5 10	1	75 60	100 100
Stage not stated		M F	3 2	1 3	1	1 3	2 8	12 12	15 5	13 11	5 5	- -	53 49	
Total	(0) 1912	M F	21 9	2 3	1 1	6 4	10 16	24 21	30 14	23 26	10 15	1	128 109	100
					Brain	(inclu	ding gli	omas not	specifie	ed as be	nign) (	ICD No. 1	93.0)	
EPo	6.1 415	M F	5 1	5 5	5 2	6 2	9 3	19 9	14 12	8 4	-		71 38	18 15
Other stage cases with metastases		M F	11 8	10 13	11 10	19 17	37 21	87 49	100 68	28 26	3 4	1 -	307 216	80 82
Metastases present	12.	M F	- 1	1 -			1 2	3	4 2	2 1		- *	8 9	2 3
Total cases staged	122 345	M F	16 10	16 18	16 12	25 19	47 26	106 61	118 82	38 31	34	1	386 263	100 100
Stage not stated	ent -	M F	14 15	29 37	12 10	22 23	58 40	104 89	157 106	47 39	7 9	-	450 368	trailare.
Total	2218 2218	M F	30 25	45 55	28 22	47 42	105 66	210 150	275 188	85 70	10 13	1 -	836 631	Teent

Stage	Sex		1			Age-g	roup			75	Age not	Total	% of all cases
Duage	Dex	0-4	5–14	15-24	25-34	35-44	45–54	55-64	65-74	and over	stated	local	staged
THE	and the second			т	hy roid g	land (IC	D No. 19	4)				for a series	
EPo	M F		- 1	- 1	$-\frac{1}{7}$	2 8	5 13	1 9	2 11	2 5	-	12 55	18 26
EPs	M F	-	-	- 1	=	2		- 1	- 1	- 1	=	- 4	- 2
LPo	M F				- 1	- 3	2 6	6 9	4 14	2 24	=	14 57	21 27
LP <sub>S</sub>	M F		-	- 1	19 <del></del> 19	1 3	2 3	3 8	4 9	5 9	-	15 33	22 16
Metastases present	M F	-	- -	=	3 3	- 1	4 9	5 21	9 14	5 13	=	26 61	39 29
Total cases staged	M F	-	- 1	-3	3 11	3 15	13 31	15 48	19 49	14 52	-	67 210	100 100
Stage not stated	M F		1 1	2 6	5 11	2 18	4 23	10 19	13 48	7 20	-	44 146	
Total	MF	-	1 2	2 9	8 22	5 33	17 54	25 67	32 97	21 72	1	111 356	025 
			Lo	ng bones	of limb	os (ICD N	los. 196.	4 and 19	6.7)				
EPo	M F	1 1	2 3	11 3	3	1	5	3 3	- 2	- 2	-	26 16	34
EPs	M	-	-	100	-	3 3	-	1 250	18 5	-	-	=	and a state
LP <sub>O</sub>	M	-	22	6 2	1 2	1	3	5 1	6 1	34		27 12	35 31
LPs	M	-	- -	-		eren ander over Lei	- 1	-	- 1		-	- 2	- 5
Metastases present	MF	-	1 2	3	4	1	1	4 2	6 3	4		24 9	31 23
Total cases staged	M	1 1	5 7	20 5	8 3	3 1	9 2	12 6	12 7	777	=	77 39	100 100
Stage not stated	M F	2 -	7 6	12 8	4 -	2 5	6 5	7 3	6 2	Б 6	Ξ	51 35	- 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10
Total	MF	3	12 13	32 13	12 3	5 6	15 7	19 9	18 9	12 13	=	128 74	100 C
					Connecti	ive tiss	Le (ICD M	lo. 197)					
EPo	M F	1 2	1 2	56	4 4	10 7	10 5	12 13	6 8	4 9		53	38 41
EPs	MF	-	1	1	Ē		- 1		1	-		3	2
LPo	MF	1	- 2	3 1	1 4	55	7 5	9 9	7 4	6 14		39 44	28 32
LP <sub>S</sub>	MF	1	-	1	3	1	- 1	2	2 2	-	1	10	7 4
Metastases present	MF	1	- 2	2 3	4 1	1 4	55	10 3	6 5	5	5	34 30	25
Total cases	M	4 3	26	12 10	12 10	17 17	22 17	33 25	22 19	15 29		139 136	100
staged Stage not	M	2	1	8	7	9	21 16	26 21	24 19	15 25	_	113 113	
stated	F	1 6	3 3	6 <b>20</b>	9 19	13 26	10 <b>43</b>	59	19 <b>46</b>	30	_	252	

## Appendix Table H. Cases of cancer of selected sites by sex, showing the total number staged and the number of early growths without clinical involvement of lymphatic glands

England and Wales, 1961

Site description	at strange it an	Males		, 1998, 19	Females	
	Total	No. staged	EP <sub>o</sub> cases	Total	No. staged	EP <sub>o</sub> cases
Base of Tongue (ICD No. 141.0)	42	21	2	9	4	
Tonsil (ICD No. 145.0)	106	63	16	55	22	3
Nasopharynx (ICD No. 146)	102	51	3	39	23	4
Pyriform fossa (ICD No. 147 part)	119	75	9	35	22	3
Post cricoid region (ICD No. 147 part)	31	21	4	142	98	30
Nose (internal) and nasal cavities	and the second	14 2 BC 9	1 to 1 1 1 1 1 1 1 1 1 1	110		00
(ICD No. 160.0)	47	21	14	24	16	11
Eustachian tube and middle ear (ICD No. 160.1)	25	17	10	14	8	5
Malignant melanoma of skin of head and neck						
(ICD Nos. 190.0-190.4)	67	38	23	96	55	43
Malignant melanoma of skin of trunk	77.00			a martin		
(ICD No. 190.5)	55	35	13	65	38	25
Malignant melanoma of skin of limbs						
(ICD Nos. 190.6 and 190.7)	94	56	24	297	170	113
Other malignant neoplasm of skin of head and neck	and a					
(ICD Nos. 191.0-191.4)*	1,032	660	545	495	302	263
ther malignant neoplasm of skin of trunk				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
(ICD No. 191.5)*	117	78	45	138	93	57
Other malignant neoplasm of skin of limbs						
(ICD Nos. 191.6-191.7)*	390	248	189	272	182	131
Spinal cord (including gliomas not specified as		10				
benign) (ICD No. 193.1) Suprarenal gland (ICD No. 195.0)	14	10	2	24	12	
	32	19	1	30	16	3
Bones of skull and face (ICD No. 196.0)	50	26	8	36	17	4

\* Excludes cases of rodent ulcer.

#### Appendix Table J.

Cases of cancer of the breast (females only) staged in accordance with the system recommended by the International Union against Cancer, by age England and Wales, 1961

	13 Las	1.2			Age-gr	oup	20			٨٣٥	
Category	0–4	5–14	15–24	25–34	35-44	45-54	55-64	65-74	75 and over	Age not stated	Total
T1 with NO and MO T2 with NO and MO	1 1		- 1	11 10	78 76	136 182	79 192	69 159	39 105	1 1	412 725
Stage   Total Percentage		14	<b>1</b> 100	<b>21</b> 28.8	<b>154</b> 42.3	<b>318</b> 39.2	<b>271</b> 33.4	<b>228</b> 35.0	<b>144</b> 30.0	1 1	<b>1,137</b> 35.6
T1 with N1 and M0 T2 with N1 and M0				7 12	33 58	35 129	31 143	29 88	7 59		142 489
Stage II Total Percentage	1		-	<b>19</b> 26.0	<b>91</b> 25.0	<b>164</b> 20.2	<b>174</b> 21.4	<b>117</b> 18.0	<b>66</b> 13.8	1 1	<b>631</b> 19.8
T1 with N2 and M0 T1 with N3 and M0 T2 with N3 and M0 T2 with N2 and M0 T3 with N3 and M0 T3 with N1 and M0 T3 with N2 and M0 T3 with N3 and M0 T4 with N1 and M0 T4 with N1 and M0 T4 with N2 and M0 T4 with N3 and M0		1 1 1 1 1 1 1 1 1 1		1 1 2 - 3 3 2 3 1 2 	1 1 4 23 40 7 6 1 9 2 2	2 1 15 4 82 96 21 9 7 12 5 7	2 2 16 9 72 89 27 16 13 18 16 11	5 -7 6 68 80 31 13 7 14 15 6	- 14 4 65 66 24 10 10 7 11 3	1 1 1 1 1 1 1 1 1 1	11 5 58 27 313 384 113 57 40 62 49 29
Stage III Total Percentage	-	- L L.	-	<b>28</b> 38.4	<b>100</b> 27.5	<b>261</b> 32.2	<b>291</b> 35.8	<b>252</b> 38.7	<b>214</b> 44.7	<b>2</b> 100	<b>1,148</b> 35.9
T1 with any N and M T2 with any N and M T3 with any N and M T4 with any N and M				1 1 1 2	2 3 8 6	6 13 30 19	2 16 30 28	2 12 20 20	2 14 22 17		15 59 111 92
Stage IV Total Percentage	-	-	-	<b>5</b> 6.8	<b>19</b> 5.2	<b>68</b> 8.4	<b>76</b> 9.4	<b>54</b> 8.3	<b>55</b> 11.5		<b>277</b> 8.7
All stages Total Percentage	100	100	1 100	73 100	364 100	811 100	812 100	651 100	479 100		3,193 100
Categories not stated	-	-	4	55	326	624	620	552	351	2	2,534

D 76350/1/Dd. 132560 K10. 12/66 TCL

Appendix Table K.

K. Cases of cancer of the cervix by age and International stage

England and Wales, 1961

	Age-group									1.000	8	d ee
International stage	0-4	5-14	15-24	25-34	35-44	45-54	55-64	65-74	75 and	Age not stated	Total	% of all cases staged
2 22		332		1 ar gu y'	10153	[79 (A)] <u>24</u>	10 20 20 10 10 10 10 10 10 10 10 10 10 10 10 10	128.21.9	over	3 4 3	a stales	L. St. parts
I	197 <del>3</del> .		1	44	171	151	142	71	22	1	603	27
II	14-5	·	2	19	183	229	219	129	65	- 5	846	37
III		io <del>d</del> es a	-	9	94	162	147	105	65	3	585	26
IV	-	-		4	25	54	49	66	20	- k	218	10
Total cases staged		-	3	76	473	596	557	371	172	4	2,252	100
Stage not stated		<del>.</del>		24	143	184	172	114	63	1	701	e spe s spe s spe s sea o
Total	-4-4	-	3	100	616	780	729	485	235	5	2,953	and a state

#### GENERAL REGISTER OFFICE

#### STUDIES ON MEDICAL AND POPULATION SUBJECTS

#### No. 20

## Accuracy of Certification of Cause of Death

A report on a survey conducted in 1959 in 75 hospitals of the National Health Service to obtain information on the extent of agreement between clinical and post-mortem diagnoses

by

#### M. A. Heasman, M.R.C.S., L.R.C.P., D.P.H.

#### and

#### L. Lipworth, M.B., Ch.B., B.Sc.

The report of an investigation into the correlation between clinical and post-mortem diagnoses in which the clinicians and pathologists in 75 teaching and nonteaching hospitals in England and Wales participated.

The results of the enquiry in relation to national mortality statistics and to selected causes of death are discussed in the report.

#### Price 21s. 0d. net (By post 21s. 8d.)

#### Published by

#### HER MAJESTY'S STATIONERY OFFICE

and obtainable from the Government Bookshops in London (post orders to P.O. Box 569, S.E.I), Edinburgh, Cardiff, Belfast, Manchester, Birmingham and Bristol, or through any bookseller © Crown copyright 1967 Printed and published by HER MAJESTY'S STATIONERY OFFICE To be purchased from 49 High Holborn, London w.c.1 423 Oxford Street, London w.1 13A Castle Street, Edinburgh 2 109 St. Mary Street, Cardiff Brazennose Street, Manchester 2 50 Fairfax Street, Bristol 1 35 Smallbrook, Ringway, Birmingham 5 7 - 11 Linenhall Street, Belfast 2 or through any bookseller

Printed in England

S.O. Code No. 70-765-0-61

·?; \*

